| Year |
Citation |
Score |
| 2024 |
Bartlett JMS, Xu K, Wong J, Pond G, Zhang Y, Spears M, Salunga R, Mallon E, Taylor KJ, Hasenburg A, Markopoulos C, Dirix L, van de Velde CJH, Rea D, Schnabel CA, et al. Validation of the prognostic performance of Breast Cancer Index (BCI) in hormone receptor-positive (HR+) postmenopausal breast cancer patients in the TEAM trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38345755 DOI: 10.1158/1078-0432.CCR-23-2436 |
0.388 |
|
| 2023 |
De Schepper M, Nguyen HL, Richard F, Rosias L, Lerebours F, Vion R, Clatot F, Berghian A, Maetens M, Leduc S, Isnaldi E, Molinelli C, Lambertini M, Grillo F, Zoppoli G, ... Dirix L, et al. Treatment response, tumor infiltrating lymphocytes and clinical outcomes in inflammatory breast cancer treated with neoadjuvant systemic therapy. Cancer Research Communications. PMID 38147006 DOI: 10.1158/2767-9764.CRC-23-0285 |
0.331 |
|
| 2023 |
Wildiers H, Armstrong A, Cuypere E, Dalenc F, Dirix L, Chan S, Marme F, Schröder CP, Huober J, Duhoux FP, Vuylsteke P, Jager A, Brain E, Kuemmel S, Pápai Z, et al. Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase 2b Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37939105 DOI: 10.1158/1078-0432.CCR-23-1173 |
0.316 |
|
| 2023 |
Richard F, De Schepper M, Maetens M, Leduc S, Isnaldi E, Geukens T, Van Baelen K, Nguyen HL, Vermeulen P, Van Laere S, Bertucci F, Ueno N, Dirix L, Floris G, Biganzoli E, et al. Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target. Breast (Edinburgh, Scotland). PMID 36717329 DOI: 10.1016/j.breast.2023.01.010 |
0.388 |
|
| 2022 |
Xu K, Bayani J, Mallon E, Pond GR, Piper T, Hasenburg A, Markopoulos CJ, Dirix L, Seynaeve CM, van de Velde CJH, Rea DW, Bartlett JMS. Discordance between Immunohistochemistry and ERBB2 mRNA to Determine HER2 Low Status for Breast Cancer. The Journal of Molecular Diagnostics : Jmd. PMID 35526835 DOI: 10.1016/j.jmoldx.2022.04.002 |
0.344 |
|
| 2022 |
Dirix L, Buys A, Oeyen S, Peeters D, Liègeois V, Prové A, Rondas D, Vervoort L, Mariën V, Laere SV, Vermeulen P. Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer. Breast Cancer Research and Treatment. PMID 35397078 DOI: 10.1007/s10549-022-06585-5 |
0.401 |
|
| 2022 |
Gerratana L, Pierga JY, Reuben JM, Davis AA, Wehbe FH, Dirix L, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, et al. Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. The Oncologist. PMID 35278078 DOI: 10.1093/oncolo/oyac045 |
0.33 |
|
| 2022 |
Dirix LY, Oeyen S, Buys A, Liégois V, Prové A, Van De Mooter T, Van Laere S, Vermeulen PB. Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer. Breast Cancer Research and Treatment. PMID 35132503 DOI: 10.1007/s10549-021-06484-1 |
0.391 |
|
| 2021 |
Fitzpatrick A, Iravani M, Mills A, Childs L, Alaguthurai T, Clifford A, Garcia-Murillas I, Van Laere S, Dirix L, Harries M, Okines A, Turner NC, Haider S, Tutt ANJ, Isacke CM. Assessing CSF ctDNA to improve diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34921020 DOI: 10.1158/1078-0432.CCR-21-3017 |
0.307 |
|
| 2021 |
Lindgren M, Jansson M, Tavelin B, Dirix L, Vermeulen P, Nyström H. Type IV collagen as a potential biomarker of metastatic breast cancer. Clinical & Experimental Metastasis. 38: 175-185. PMID 33655422 DOI: 10.1007/s10585-021-10082-2 |
0.348 |
|
| 2020 |
Berckelaer CV, Geyt MV, Linders S, Rypens C, Trinh XB, Tjalma WAA, Laere SV, Colpaert C, Dirix L, Dam PAv. A high Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio are associated with a worse outcome in Inflammatory Breast Cancer The Breast. 53: 212-220. PMID 32890963 DOI: 10.1016/J.Breast.2020.08.006 |
0.49 |
|
| 2020 |
Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, Mavroudis D, Garcia-Saenz JA, Stebbing J, ... ... Dirix L, et al. Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy. Journal of the National Cancer Institute. PMID 32770247 DOI: 10.1093/Jnci/Djaa113 |
0.491 |
|
| 2020 |
Latacz E, van Dam PJ, Vanhove C, Llado L, Descamps B, Ruiz N, Joye I, Grünhagen D, Van Laere S, Dirix P, Mollevi D, Verhoef C, Dirix L, Vermeulen P. Can medical imaging identify the histopathological growth patterns of liver metastases? Seminars in Cancer Biology. PMID 32735852 DOI: 10.1016/J.Semcancer.2020.07.002 |
0.357 |
|
| 2020 |
Iwase T, Harano K, Masuda H, Kida K, Hess KR, Wang Y, Dirix L, Van Laere SJ, Lucci A, Krishnamurthy S, Woodward WA, Layman RM, Bertucci F, Ueno NT. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. Bmc Cancer. 20: 430. PMID 32423453 DOI: 10.1186/S12885-020-06940-Z |
0.434 |
|
| 2020 |
Dirix P, Strijbos M, den Mooter TV, Liefhooghe N, Bruwaene SV, Uvin P, Ghysel C, Ost D, Schatteman P, Bral S, Engels B, den Begin RV, Otte FX, Roumeguere T, Palumbo S, ... ... Dirix L, et al. Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy. Future Oncology (London, England). 16: 1083-1189. PMID 32356465 DOI: 10.2217/Fon-2020-0056 |
0.34 |
|
| 2020 |
Walker JW, Lebbé C, Grignani G, Nathan P, Dirix L, Fenig E, Ascierto PA, Sandhu S, Munhoz R, Benincasa E, Flaskett S, Reed J, Engelsberg A, Hariharan S, Kasturi V. Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. Journal For Immunotherapy of Cancer. 8. PMID 32269140 DOI: 10.1136/Jitc-2019-000313 |
0.304 |
|
| 2020 |
Rypens C, Marsan M, Van Berckelaer C, Billiet C, Melis K, Lopez SP, van Dam P, Devi GR, Finetti P, Ueno NT, Bertucci F, Dirix P, Neven P, Vermeulen P, Dirix L, et al. Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity. Breast Cancer Research and Treatment. PMID 32043194 DOI: 10.1007/S10549-020-05571-Z |
0.478 |
|
| 2020 |
Berckelaer CV, Rypens C, Laere SV, Marien K, Dam PV, Vermeulen PB, Colpaert C, Dirix LY, Kockx M, Dam PV. The spatial localization of CD163+ tumor-associated macrophages predicts prognosis and response to therapy in inflammatory breast cancer. Journal of Clinical Oncology. 38: 3086-3086. DOI: 10.1200/Jco.2020.38.15_Suppl.3086 |
0.429 |
|
| 2020 |
Berckelaer CV, Rypens C, Laere SV, Marien K, Dam Pv, Vermeulen P, Dirix L, Kockx M, Colpaert C, Dam Pv. Abstract P5-04-04: The spatial interactions between FOXP3+ Tregs, CD8+ cytotoxic T cells and tumor cells predict response to therapy and prognosis in inflammatory breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P5-04-04 |
0.396 |
|
| 2020 |
Rypens C, Bertucci F, Viens P, Martens JW, Smid M, Schröder C, Ueno NT, Cristofanilli M, Dirix P, Vermeulen P, Dirix L, Laere SV. Abstract P3-03-03: Inflammatory breast cancer exhibits amplification and transcriptional activation of MYC in conjunction with NOTCH and TGFβ signaling Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-03-03 |
0.449 |
|
| 2020 |
Vermeulen PB, Bohlok A, Leduc S, Richard F, Botzenhart L, Ignatiadis M, Aftimos P, Sotiriou C, Piccart M, Hendlisz A, Laere SV, Dirix LY, Noël J, Lucidi V, Biganzoli E, et al. Abstract P3-01-13: Association between the histopathological growth patterns (HGP) of liver metastases (LM) and survival after hepatic surgery in patients with oligometastatic breast cancer (BC) Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-01-13 |
0.425 |
|
| 2020 |
Peeters D, Buys A, Ledegen H, Moehlig K, Oeyen S, Rondas D, Beukelaer AD, Laere SV, Vervoort L, Vermeulen P, Ung C, Kockx M, Dirix L. Abstract OT3-18-02: A comparative study of two detection platforms of circulating tumour cells in patients with metastatic breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-Ot3-18-02 |
0.49 |
|
| 2020 |
Dirix L, Wildiers H, Huizing MT, Cuypere ED, Schröder CP, Armstrong AC, Huober J, Marmé F, Schneeweiss A, Khan S, Triebel F. Abstract OT1-01-05: AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Ot1-01-05 |
0.47 |
|
| 2019 |
Bertucci F, Rypens C, Finetti P, Guille A, Adelaïde J, Monneur A, Carbuccia N, Garnier S, Dirix P, Gonçalves A, Vermeulen P, Debeb BG, Wang X, Dirix L, Ueno NT, et al. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. Molecular Oncology. PMID 31854063 DOI: 10.1002/1878-0261.12621 |
0.396 |
|
| 2019 |
Sharma P, Sohn J, Shin SJ, Oh DY, Keam B, Lee HJ, Gizzi M, Kalinka E, de Vos FYFL, Ruscica D, Ferro S, Xiao F, Baverel P, Chen CC, Asubonteng K, ... ... Dirix L, et al. Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31801732 DOI: 10.1158/1078-0432.Ccr-19-1635 |
0.336 |
|
| 2019 |
Latacz E, Caspani E, Barnhill R, Lugassy C, Verhoef C, Grünhagen D, Van Laere S, Fernández Moro C, Gerling M, Dirix M, Dirix LY, Vermeulen PB. Pathological features of vessel co-option versus sprouting angiogenesis. Angiogenesis. PMID 31655928 DOI: 10.1007/S10456-019-09690-0 |
0.341 |
|
| 2019 |
Dummer R, Guminksi A, Gutzmer R, Lear JT, Lewis KD, Chang ALS, Combemale P, Dirix L, Kaatz M, Kudchadkar R, Loquai C, Plummer R, Schulze HJ, Stratigos AJ, Trefzer U, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase 2 randomised, double-blind BOLT study. The British Journal of Dermatology. PMID 31545507 DOI: 10.1111/Bjd.18552 |
0.318 |
|
| 2019 |
Brouwer A, De Laere B, van Dam PJ, Peeters D, Van Haver J, Sluydts E, El Moussaoui A, Mendelaar P, Kraan J, Peeters M, Van Laere S, Dirix L. HER-2 status of circulating tumor cells in a metastatic breast cancer cohort: A comparative study on characterization techniques. Plos One. 14: e0220906. PMID 31483799 DOI: 10.1371/Journal.Pone.0220906 |
0.465 |
|
| 2019 |
Dirix L. Predictive Significance of Androgen Receptor Splice Variant 7 in Patients With Metastatic Castration-Resistant Prostate Cancer: The PROPHECY Study. Journal of Clinical Oncology. 37: 2180-2181. PMID 31265358 DOI: 10.1200/Jco.19.00811 |
0.329 |
|
| 2019 |
Sieuwerts AM, Onstenk W, Kraan J, Beaufort CM, Van M, De Laere B, Dirix LY, Hamberg P, Beeker A, Meulenbeld HJ, Creemers GJ, van Weerden WM, Jenster GW, Nieuweboer AJM, Mathijssen RHJ, et al. AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel. Molecular Oncology. PMID 31180178 DOI: 10.1002/1878-0261.12529 |
0.36 |
|
| 2019 |
De Laere B, Rajan P, Grönberg H, Dirix L, Lindberg J. Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer. Jama Oncology. PMID 31046065 DOI: 10.1001/Jamaoncol.2019.0869 |
0.329 |
|
| 2019 |
Dirix L, Triebel F. AIPAC: a Phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer. Future Oncology. 15: 1963-1973. PMID 30977393 DOI: 10.2217/Fon-2018-0807 |
0.474 |
|
| 2019 |
Van Berckelaer C, Rypens C, van Dam P, Pouillon L, Parizel M, Schats KA, Kockx M, Tjalma WAA, Vermeulen P, van Laere S, Bertucci F, Colpaert C, Dirix L. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression. Breast Cancer Research : Bcr. 21: 28. PMID 30777104 DOI: 10.1186/S13058-019-1108-1 |
0.424 |
|
| 2019 |
Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, ... ... Dirix L, et al. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Critical Reviews in Oncology/Hematology. 134: 39-45. PMID 30771872 DOI: 10.1016/J.Critrevonc.2018.12.004 |
0.478 |
|
| 2019 |
Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, ... ... Dirix L, et al. Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. PMID 30659290 DOI: 10.1038/S41586-019-0883-2 |
0.319 |
|
| 2019 |
Galjart B, Nierop PMH, van der Stok EP, van den Braak RRJC, Höppener DJ, Daelemans S, Dirix LY, Verhoef C, Vermeulen PB, Grünhagen DJ. Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases. Angiogenesis. 22: 355-368. PMID 30637550 DOI: 10.1007/S10456-019-09661-5 |
0.338 |
|
| 2019 |
Derks MGM, Velde CJHvd, Giardiello D, Seynaeve C, Putter H, Nortier JWR, Dirix LY, Bastiaannet E, Portielje JEA, Liefers G. Impact of Comorbidities and Age on Cause‐Specific Mortality in Postmenopausal Patients with Breast Cancer Oncologist. 24. PMID 30606886 DOI: 10.1634/Theoncologist.2018-0010 |
0.462 |
|
| 2019 |
Apolo AB, Patel MR, Ellerton JA, Dirix L, Manitz J, Kasturi V, Warth J, Rosen G, Gulley JL. Avelumab treatment in metastatic urothelial carcinoma: Post-hoc analysis of high-risk populations in the phase Ib JAVELIN Solid Tumor Study. Journal of Clinical Oncology. 37: 428-428. DOI: 10.1200/Jco.2019.37.7_Suppl.428 |
0.304 |
|
| 2019 |
Apolo AB, Ellerton JA, Infante JR, Agrawal M, Gordon MS, Aljumaily R, Britten CD, Dirix L, Lee K, Taylor MH, Schoffski P, Wang D, Ravaud A, Xiong J, Rosen G, et al. Avelumab treatment for metastatic urothelial carcinoma in the phase Ib JAVELIN Solid Tumor Study: Updated safety and efficacy analysis with ≥ two years of follow-up. Journal of Clinical Oncology. 37: 425-425. DOI: 10.1200/Jco.2019.37.7_Suppl.425 |
0.352 |
|
| 2019 |
Brufsky A, Kim S, Zvirbule Z, Dirix LY, Eniu AE, Carabantes F, Izarzugaza Y, Mebis J, Sohn J, Wongchenko M, Chohan S, Amin R, McNally VA, Miles D, Loi S. Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC). Journal of Clinical Oncology. 37: 1013-1013. DOI: 10.1200/Jco.2019.37.15_Suppl.1013 |
0.427 |
|
| 2019 |
Vermeulen P, Dam Pv, Daelemans S, Latacz E, Joye I, Kockx M, Dirix P, Verhoef K, Grunhagen D, Huget P, Laere SV, Dirix L. Abstract PD9-08: Breast cancer liver metastases vascularize by vessel co-option, not angiogenesis, and have a desert immune phenotype: A histopathological and gene expression study Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd9-08 |
0.468 |
|
| 2019 |
Iwase T, Harano K, Masuda H, Kida K, Fernandez JE, Hess K, Wang Y, Woodward W, Layman R, Dirix L, Laere SV, Bertucci F, Ueno N. Abstract P5-05-04: Myc as a poor prognostic marker for ER+ inflammatory breast cancer (IBC): Quantitative estrogen receptor (ER) expression analysis and gene expression analysis in ER+ IBC vs non-IBC Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P5-05-04 |
0.404 |
|
| 2019 |
Berckelaer CV, Colpaert C, Rypens C, Marien K, Waumans Y, Kockx M, Vermeulen P, Dirix L, Laere SV, Dam PV. Abstract P4-06-08: The spatial localization of immune cells predicts prognosis and response to therapy in inflammatory breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P4-06-08 |
0.406 |
|
| 2019 |
Laere SV, Finetti P, Rypens C, Billet C, Birnbaum D, Vermeulen P, Viens P, Dirix L, Bertucci F. Abstract P4-04-04: The mutational profile of inflammatory breast cancer reveals a higher mutational burden leading to MAPK activation and chromatin remodeling Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P4-04-04 |
0.37 |
|
| 2019 |
Rypens C, Berckelaer CV, Billet C, Hauspy J, Bertucci F, Peter V, Dirix L, Laere SV. Abstract P2-01-15: Inflammatory breast cancer cells are characterized by attenuated SMAD dependent TGFβ signaling leading to impaired cell motility responses Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P2-01-15 |
0.411 |
|
| 2019 |
Dirix P, Strijbos M, Fransis K, Liefhooghe N, Van Bruwaene S, Uvin P, Ghysel C, Ost D, Engels B, Van den Begin R, Otte F, Roumeguere T, Palumbo S, Neybuch Y, Fonteyne V, ... ... Dirix L, et al. A phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy with LHRH agonist or antagonist versus anti-androgen therapy with apalutamide in patients with biochemical progression after radical prostatectomy Annals of Oncology. 30: v355. DOI: 10.1093/Annonc/Mdz248.057 |
0.336 |
|
| 2019 |
Laere BD, Crippa A, Ghysel C, Ost P, Rajan P, Eklund M, Dirix L, Grönberg H, Lindberg J. Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz239.017 |
0.409 |
|
| 2019 |
Goethem AV, Rypens C, Rutten A, Mooter TVd, Erven K, Havenbergh TV, Prové A, Laere SJV, Vermeulen P, Dirix LY. Sensitivity and dynamic range of CellSearch based CSF DTC enumeration in patients with breast cancer related leptomeningeal metastases (LM). Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz100.038 |
0.451 |
|
| 2019 |
Rypens C, Berckelaer CV, Billiet C, Hauspy J, Bertucci F, Devi G, Vermeulen P, Dirix LY, Laere SJV. Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity. Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz095.071 |
0.423 |
|
| 2019 |
Berckelaer CV, Colpaert CG, Rypens C, Marien K, Kockx M, Waumans Y, Vermeulen P, Dirix LY, Laere SJV, Dam PV. The spatial relations among immune cells are prognostic in inflammatory breast cancer Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz095.030 |
0.411 |
|
| 2019 |
Machiels M, Weytjens R, Erven K, Westerhoff J, Amrouch S, Bosiers J, Verkinderen L, Hauspy J, Van Dam P, Dirix P, Vos M, Huget P, Dirix L, Meijnders P, Van Laere S, et al. PO-0765 Oncological and cosmetic outcome after IOERT as a boost in a large cohort of breast cancer patients. Radiotherapy and Oncology. 133: S393-S394. DOI: 10.1016/S0167-8140(19)31185-5 |
0.453 |
|
| 2018 |
Haider S, Yao CQ, Sabine VS, Grzadkowski M, Stimper V, Starmans MHW, Wang J, Nguyen F, Moon NC, Lin X, Drake C, Crozier CA, Brookes CL, van de Velde CJH, Hasenburg A, ... ... Dirix LY, et al. Pathway-based subnetworks enable cross-disease biomarker discovery. Nature Communications. 9: 4746. PMID 30420699 DOI: 10.1038/S41467-018-07021-3 |
0.315 |
|
| 2018 |
Plummer R, Verheul HM, De Vos FYFL, Leunen K, Molife LR, Rolfo C, Grundtvig-Sørensen P, De Grève J, Rottey S, Jerusalem G, Italiano A, Spicer J, Dirix L, Goessl C, Birkett J, et al. Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours. Advances in Therapy. PMID 30324586 DOI: 10.1007/S12325-018-0804-Z |
0.416 |
|
| 2018 |
Vitale SR, Sieuwerts AM, Beije N, Kraan J, Angus L, Mostert B, Reijm EA, Van NM, van Marion R, Dirix LY, Hamberg P, de Jongh FE, Jager A, Foekens JA, Vigneri P, et al. An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA. The Journal of Molecular Diagnostics : Jmd. PMID 30296589 DOI: 10.1016/J.Jmoldx.2018.08.010 |
0.376 |
|
| 2018 |
De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, ... ... Dirix LY, et al. TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30209161 DOI: 10.1158/1078-0432.Ccr-18-1943 |
0.332 |
|
| 2018 |
Roseweir AK, Bennett L, Dickson A, Cheng K, Quintayo MA, Bayani J, McMillan DC, Horgan PG, van de Velde CJH, Seynaeve C, Hasenburg A, Kieback DG, Markopoulos C, Dirix LY, Rea DW, et al. Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial. Journal of the National Cancer Institute. 110: 616-627. PMID 29917140 DOI: 10.1093/Jnci/Djx255 |
0.405 |
|
| 2018 |
Derks MGM, Bastiaannet E, Water Wvd, Glas NAd, Seynaeve C, Putter H, Nortier JWR, Rea D, Hasenburg A, Markopoulos C, Dirix LY, Portielje JEA, Velde CJHvd, Liefers GJ. Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial. European Journal of Cancer. 99: 1-8. PMID 29885375 DOI: 10.1016/J.Ejca.2018.04.009 |
0.435 |
|
| 2018 |
Spigel DR, Chaft JE, Gettinger S, Chao BH, Dirix L, Schmid P, Chow LQM, Hicks RJ, Leon L, Fredrickson J, Kowanetz M, Sandler A, Funke R, Rizvi NA. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients with Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29775807 DOI: 10.1016/J.Jtho.2018.05.004 |
0.319 |
|
| 2018 |
Dirix LY. Adjuvant aromatase inhibition: more options for patients. Lancet Oncology. 19: 431-432. PMID 29482984 DOI: 10.1016/S1470-2045(18)30155-4 |
0.317 |
|
| 2018 |
Sieuwerts AM, Mostert B, Vlugt-Daane Mvd, Kraan J, Beaufort CM, Van M, Prager WJC, Laere BD, Beije N, Hamberg P, Westgeest HM, Tascilar M, Dirix LY, Onstenk W, Wit Rd, et al. An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells. The Journal of Molecular Diagnostics. 20: 316-325. PMID 29474983 DOI: 10.1016/J.Jmoldx.2018.01.008 |
0.334 |
|
| 2018 |
De Laere B, Oeyen S, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert E, Van Kerckhove P, De Maeseneer D, Strijbos M, ... ... Dirix L, et al. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer. The Prostate. PMID 29431193 DOI: 10.1002/Pros.23488 |
0.359 |
|
| 2018 |
van Dam PJ, Daelemans S, Ross E, Waumans Y, Laere SV, Latacz E, Steen RV, Pooter C, Kockx M, Dirix L, Vermeulen PB. Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy. Seminars in Cancer Biology. PMID 29355613 DOI: 10.1016/J.Semcancer.2018.01.009 |
0.336 |
|
| 2018 |
Sharma P, Dirix L, De Vos FYFL, Allison JP, Decoster L, Zaucha R, Park JO, Vanderwalde AM, Kataria RS, Ferro S, Patel G, Ben Y(, Oh D. Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma. Journal of Clinical Oncology. 36: 470-470. DOI: 10.1200/Jco.2018.36.4_Suppl.470 |
0.335 |
|
| 2018 |
Dirix L, Jager A, Marme F, Brain E, Armstrong AC, Nawrocki S, Triebel F. AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps1109 |
0.357 |
|
| 2018 |
Duhoux FP, Jager A, Dirix LY, Huizing MT, Jerusalem GHM, Vuylsteke P, Cuypere ED, Breiner D, Mueller C, Brignone C, Triebel F. Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II. Journal of Clinical Oncology. 36: 1050-1050. DOI: 10.1200/Jco.2018.36.15_Suppl.1050 |
0.32 |
|
| 2018 |
Davis AA, Pierga J, Dirix LY, Michiels S, Rademaker A, Reuben JM, Fehm TN, Munzone E, Giuliano M, Vidal-Martinez J, Mavroudis D, Grisanti S, Generali DG, Garcia-Saenz JA, Stebbing J, et al. The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of “indolent” stage IV disease (Stage IVindolent). Journal of Clinical Oncology. 36: 1019-1019. DOI: 10.1200/Jco.2018.36.15_Suppl.1019 |
0.443 |
|
| 2018 |
Bayani J, Kornaga E, Crozier C, Jang G, Kalatskaya I, Trinh Q, Yao C, Livingstone J, Hasenburg A, Kieback D, Markopoulos C, Dirix L, Boutros P, Spears M, Stein L, et al. Abstract PD4-11: Copy-number and targeted sequencing analyses to identify distinct prognostic groups: Implications for patient selection to targeted therapies amongst anti-endocrine therapy resistant early breast cancers Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Pd4-11 |
0.472 |
|
| 2018 |
Bayani J, Crozier C, Quintayo M, Amemiya Y, Zhang X, Larivière M, Sadis S, Smith J, Hasenburg A, Kieback D, Markopoulos C, Dirix L, Yaffe M, Seth A, Feilotter H, et al. Abstract P2-09-17: Evaluation of the oncomine comprehensive assay for the identification of actionable mutations for therapeutic stratification from the TEAM pathology cohort Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P2-09-17 |
0.418 |
|
| 2018 |
Bartlett J, Thomas J, Mallon E, Piper T, Bayani J, Hasenburg A, Kieback D, Markopoulos C, Dirix L, Seynaeve C, Velde Cvd, Rea D. Abstract P1-06-04: Simplified histological grading of breast carcinoma – potential for improved concordance and consistency in breast cancer grading? Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P1-06-04 |
0.45 |
|
| 2018 |
McNair C, Xu K, Mandigo AC, Benelli M, Leiby B, Rodrigues D, Lindberg J, Gronberg H, Laere BD, Dirix L, Visakorpi T, Li F, Feng FY, Bono Jd, Demichelis F, et al. Abstract IA03: Differential impact of RB pathway status on E2F1 reprogramming and disease progression in human prostate cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-Ia03 |
0.347 |
|
| 2018 |
McNair C, Xu K, Mandigo AC, Benelli M, Leiby B, Rodrigues D, Lindberg J, Gronberg H, Crespo M, Laere BD, Dirix L, Visakorpi T, Li F, Feng FY, Bono Jd, et al. Abstract B040: Differential impact of RB status on E2F1 reprogramming in human cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-B040 |
0.317 |
|
| 2018 |
Bardia A, Modi S, Cortes J, Campone M, Dirix L, Ma B, Beck JT, Chaves J, Weise A, Vuky J, Lopes G, Gil-Gil M, Liu X, He W, Su F, et al. Abstract CT069: Baseline gene expression patterns of CDK4/6 inhibitor-naïve or -refractory HR+, HER2- advanced breast cancer in the phase Ib study of ribociclib plus everolimus plus exemestane Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct069 |
0.432 |
|
| 2018 |
Sieuwerts AM, Mostert B, Vlugt-Daane Mvd, Kraan J, Beaufort C, Van M, Prager WJ, Laere BD, Beije N, Hamberg P, Westgeest HM, Tascilar M, Dirix LY, Onstenk W, Wit Rd, et al. Abstract 2617: A multicenter project to test the validity and logistics surrounding the testing of AR-V7 mRNA expression in circulating tumor cells Cancer Research. 78: 2617-2617. DOI: 10.1158/1538-7445.Am2018-2617 |
0.366 |
|
| 2018 |
Dam PV, Wouters A, Dirix L, Rolfo C. Abstract 2317: Palbociclib monotherapy exhibits potent activity in cervical cancer cell lines Cancer Research. 78: 2317-2317. DOI: 10.1158/1538-7445.Am2018-2317 |
0.362 |
|
| 2017 |
Migden MR, Chang ALS, Dirix L, Stratigos AJ, Lear JT. Emerging trends in the treatment of advanced basal cell carcinoma. Cancer Treatment Reviews. 64: 1-10. PMID 29407368 DOI: 10.1016/J.Ctrv.2017.12.009 |
0.359 |
|
| 2017 |
Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R, Britten CD, Dirix L, Lee KW, Taylor M, Schöffski P, Wang D, Ravaud A, Gelb AB, Xiong J, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. The Lancet. Oncology. PMID 29217288 DOI: 10.1016/S1470-2045(17)30900-2 |
0.323 |
|
| 2017 |
McNair C, Xu K, Mandigo AC, Benelli M, Leiby B, Rodrigues D, Lindberg J, Gronberg H, Crespo M, De Laere B, Dirix L, Visakorpi T, Li F, Feng FY, de Bono J, et al. Differential impact of RB status on E2F1 reprogramming in human cancer. The Journal of Clinical Investigation. PMID 29202480 DOI: 10.1172/Jci93566 |
0.34 |
|
| 2017 |
Calvo E, Azaro A, Rodon J, Dirix L, Huizing M, Senecal FM, LoRusso P, Yee L, Poggesi I, de Jong J, Triantos S, Park YC, Knoblauch RE, Parekh TV, Demetri GD, et al. Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial. Investigational New Drugs. PMID 29177975 DOI: 10.1007/S10637-017-0546-9 |
0.349 |
|
| 2017 |
Beije N, Sieuwerts AM, Kraan J, Van NM, Wendy O, Vitale SR, van der Vlugt-Daane M, Dirix LY, Brouwer A, Hamberg P, de Jongh FE, Jager A, Seynaeve CM, Jansen MPHM, Foekens JA, et al. Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients. Molecular Oncology. PMID 29063679 DOI: 10.1002/1878-0261.12147 |
0.378 |
|
| 2017 |
Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, Lippman ME, Somer R, Smakal M, Emens LA, Hrinczenko B, Edenfield W, Gurtler J, von Heydebreck A, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Research and Treatment. PMID 29063313 DOI: 10.1007/S10549-017-4537-5 |
0.366 |
|
| 2017 |
Lear JT, Migden MR, Lewis KD, Chang ALS, Guminski A, Gutzmer R, Dirix L, Combemale P, Stratigos A, Plummer R, Castro H, Yi T, Mone M, Zhou J, Trefzer U, et al. Long-Term Efficacy and Safety of Sonidegib in Patients With Locally Advanced and Metastatic Basal Cell Carcinoma: 30-Month Analysis of the Randomized Phase 2 BOLT Study. Journal of the European Academy of Dermatology and Venereology : Jeadv. PMID 28846163 DOI: 10.1111/Jdv.14542 |
0.344 |
|
| 2017 |
Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg EM, Liefers GJ, Putter H, Kroep JR, Rea D, Hasenburg A, Markopoulos C, Paridaens R, Smeets JBE, Dirix LY, van de Velde CJH. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology. PMID 28732650 DOI: 10.1016/S1470-2045(17)30419-9 |
0.452 |
|
| 2017 |
Bayani J, Yao CQ, Quintayo MA, Yan F, Haider S, D'Costa A, Brookes CL, van de Velde CJH, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Rea D, Boutros PC, et al. Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine. Npj Breast Cancer. 3: 3. PMID 28649643 DOI: 10.1038/s41523-016-0003-5 |
0.34 |
|
| 2017 |
Joglekar-Javadekar M, Van Laere S, Bourne M, Moalwi M, Finetti P, Vermeulen PB, Birnbaum D, Dirix LY, Ueno N, Carter M, Rains J, Ramachandran A, Bertucci F, van Golen KL. Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC). Neoplasia (New York, N.Y.). 19: 564-573. PMID 28609680 DOI: 10.1016/J.Neo.2017.03.002 |
0.468 |
|
| 2017 |
Massard C, Chi KN, Castellano D, de Bono J, Gravis G, Dirix L, Machiels JP, Mita A, Mellado B, Turri S, Maier J, Csonka D, Chakravartty A, Fizazi K. Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44]. European Journal of Cancer (Oxford, England : 1990). PMID 28606464 DOI: 10.1016/J.Ejca.2017.05.003 |
0.37 |
|
| 2017 |
Massard C, Chi KN, Castellano D, de Bono J, Gravis G, Dirix L, Machiels JP, Mita A, Gonzalez BM, Turri S, Maier J, Csonka D, Chakravartty A, Fizazi K. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. European Journal of Cancer (Oxford, England : 1990). 76: 36-44. PMID 28282611 DOI: 10.1016/J.Ejca.2017.01.024 |
0.329 |
|
| 2017 |
De Laere B, van Dam PJ, Whitington T, Mayrhofer M, Diaz EH, Van den Eynden G, Vandebroek J, Del-Favero J, Van Laere S, Dirix L, Grönberg H, Lindberg J. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns. European Urology. PMID 28104311 DOI: 10.1016/J.Eururo.2017.01.011 |
0.319 |
|
| 2017 |
Patel MR, Ellerton JA, Infante JR, Agrawal M, Gordon MS, Aljumaliy R, Britten CD, Dirix L, Lee K, Taylor MH, Schöffski P, Wang D, Ravaud A, Gelb A, Xiong J, et al. Avelumab in patients with metastatic urothelial carcinoma: Pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial. Journal of Clinical Oncology. 35: 330-330. DOI: 10.1200/Jco.2017.35.6_Suppl.330 |
0.336 |
|
| 2017 |
Bayani J, Kornaga E, Crozier C, Jang GH, Kalatskaya I, Trinh QM, Yao CQ, Livingstone J, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Boutros PC, Spears M, Stein LD, et al. Copy-number and targeted sequencing analyses to identify distinct prognostic groups: Implications for patient selection to targeted therapies amongst anti-endocrine therapy resistant early breast cancers. Journal of Clinical Oncology. 35: 524-524. DOI: 10.1200/Jco.2017.35.15_Suppl.524 |
0.447 |
|
| 2017 |
Laere BD, Oyen PV, Ghysel C, Ost P, Demey W, Hoekx L, Schrijvers DL, Brouwers BAH, Lybaert W, Everaert EG, Ampe J, Kerckhove PV, Maeseneer DJD, Strijbos MH, Bols A, ... ... Dirix LY, et al. Circulating tumour cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer. Journal of Clinical Oncology. 35: 5049-5049. DOI: 10.1200/Jco.2017.35.15_Suppl.5049 |
0.357 |
|
| 2017 |
Apolo AB, Ellerton JA, Infante JR, Agrawal M, Gordon MS, Aljumaily R, Britten CD, Dirix LY, Lee K, Taylor MH, Schöffski P, Wang D, Ravaud A, Gelb A, Xiong J, et al. Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study. Journal of Clinical Oncology. 35: 4528-4528. DOI: 10.1200/Jco.2017.35.15_Suppl.4528 |
0.336 |
|
| 2017 |
Duhoux FP, Jager A, Dirix L, Huizing MT, Jerusalem GHM, Vuylsteke P, Cuypere ED, Breiner D, Mueller C, Brignone C, Triebel F. Combination of paclitaxel and LAG3-Ig (IMP321), a novel MHC class II agonist, as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Interim results from the run-in phase of a placebo controlled randomized phase II. Journal of Clinical Oncology. 35: 1062-1062. DOI: 10.1200/Jco.2017.35.15_Suppl.1062 |
0.365 |
|
| 2017 |
Brufsky A, Kim S, Velu T, García-Saenz J, Tan-Chiu E, Sohn J, Dirix L, Borms M, Liu M, Moezi M, Kozloff M, Sparano J, Xu N, Wongchenko M, Simmons B, et al. Abstract P4-22-22: Cobimetinib (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (COLET study): Updated clinical and biomarker results Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P4-22-22 |
0.443 |
|
| 2017 |
Brouwer A, Verhoest F, Vermeulen P, Rutten A, Prové A, Laere SV, Peeters M, Dirix L. Abstract P3-05-10: Evaluation of HER2 expression and amplification on CTCs using DEPArray analysis and sorting followed by FISH Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-05-10 |
0.455 |
|
| 2017 |
Berckelaer CV, Parizel M, Dam PV, Dirix L, Rypens C, Bertucci F, Schats K, Kockx M, Laere SV, Colpaert C. Abstract P2-04-09: The prognostic and predictive effect of tumor infiltrating lymphocytes is not determined by B-cells or PD-L1 expression in inflammatory breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P2-04-09 |
0.402 |
|
| 2017 |
Brouwer A, Dam Pv, Rutten A, Prové A, Peeters M, Laere SV, Dirix L. Abstract P1-06-01: Evaluation of subclonality in the CTC and DTC compartment of patients with metastatic breast cancer using low pass whole genome and AmpliSeq panel sequencing Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-06-01 |
0.425 |
|
| 2017 |
Sieuwerts A, Beije N, Kraan J, Van M, Onstenk W, Vitale S, Daane MvdV–, Hamberg P, Dirix L, Brouwers A, Jongh Fd, Jager A, Seynaeve C, Jansen M, Foekens J, et al. Abstract P1-02-02:ESR1mutations in circulating tumor cell versus circulating cell-free DNA of metastatic breast cancer patients before first-line endocrine therapy and at progression Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-02-02 |
0.399 |
|
| 2017 |
Ignatiadis M, Rothé F, Peeters D, Rouas G, Smeets D, Haan J, Lambrechts D, Campbell P, Piccart M, Voet T, Dirix L, Venet D, Sotiriou C. Abstract P1-01-10: Exome sequencing of circulating tumor cells in metastatic breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-01-10 |
0.417 |
|
| 2017 |
Juric D, Campone M, Munster P, Ismail-Khan R, Estévez LG, Chavez-MacGregor M, Frassoldati A, Hui R, Mayer IA, Cortés J, Gonçalves A, Boer RHD, Dirix L, Tolaney SM, Lee SC, et al. Abstract CT087: Ribociclib + endocrine therapy (ET) doublet combinations in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Phase I clinical activity and impact of molecular alterations Clinical Trials. 77. DOI: 10.1158/1538-7445.Am2017-Ct087 |
0.388 |
|
| 2017 |
Apolo AB, Ellerton J, Infante JR, Agrawal M, Gordon MS, Aljumaily R, Britten CD, Dirix L, Lee K, Taylor MH, Schöffski P, Wang D, Ravaud A, Gelb A, Xiong J, et al. 856PAvelumab treatment of metastatic urothelial carcinoma (mUC) in the phase 1b JAVELIN solid Tumor study: updated analysis with ≥6 months of follow-up in all patients Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx371.010 |
0.34 |
|
| 2016 |
Martín M, Chan A, Dirix L, O'Shaughnessy J, Hegg R, Manikhas A, Shtivelband M, Krivorotko P, Batista López N, Campone M, Ruiz Borrego M, Khan QJ, Beck JT, Ramos Vázquez M, Urban P, et al. A randomized adaptive phase II/III study of buparlisib, a pan-Class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4). Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 27803006 DOI: 10.1093/Annonc/Mdw562 |
0.444 |
|
| 2016 |
Beije N, Onstenk W, Kraan J, Sieuwerts AM, Hamberg P, Dirix LY, Brouwer A, de Jongh FE, Jager A, Seynaeve CM, Van NM, Foekens JA, Martens JW, Sleijfer S. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. Neoplasia (New York, N.Y.). 18: 647-653. PMID 27764697 DOI: 10.1016/J.Neo.2016.08.007 |
0.461 |
|
| 2016 |
Frentzas S, Simoneau E, Bridgeman VL, Vermeulen PB, Foo S, Kostaras E, Nathan MR, Wotherspoon A, Gao ZH, Shi Y, Van den Eynden G, Daley F, Peckitt C, Tan X, Salman A, ... ... Dirix L, et al. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nature Medicine. PMID 27748747 DOI: 10.1038/Nm.4197 |
0.387 |
|
| 2016 |
Dirix L, Swaisland H, Verheul HM, Rottey S, Leunen K, Jerusalem G, Rolfo C, Nielsen D, Molife LR, Kristeleit R, Vos-Geelen J, Mau-Sørensen M, Soetekouw P, van Herpen C, Fielding A, et al. Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies. Clinical Therapeutics. PMID 27745744 DOI: 10.1016/J.Clinthera.2016.08.010 |
0.371 |
|
| 2016 |
Prové A, Dirix L. Neratinib for the treatment of breast cancer Expert Opinion On Pharmacotherapy. 17: 2243-2248. PMID 27690680 DOI: 10.1080/14656566.2016.1244528 |
0.441 |
|
| 2016 |
Ramirez-Ardila DE, Ruigrok-Ritstier K, Helmijr JC, Look MP, van Laere S, Dirix L, Berns EM, Jansen MP. LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome. Molecular Oncology. PMID 27491861 DOI: 10.1016/J.Molonc.2016.07.004 |
0.399 |
|
| 2016 |
Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, ... ... Dirix L, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. PMID 27135926 DOI: 10.1038/Nature17676 |
0.326 |
|
| 2016 |
Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Gogov S, Pallaud C, Yi T, et al. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. Journal of the American Academy of Dermatology. PMID 27067394 DOI: 10.1016/J.Jaad.2016.02.1226 |
0.376 |
|
| 2016 |
Brouwer A, De Laere B, Peeters D, Peeters M, Salgado R, Dirix L, Van Laere S. Evaluation and consequences of heterogeneity in the circulating tumor cell compartment. Oncotarget. PMID 26980749 DOI: 10.18632/Oncotarget.8015 |
0.345 |
|
| 2016 |
Reijm EA, Sieuwerts AM, Smid M, Vries JB, Mostert B, Onstenk W, Peeters D, Dirix LY, Seynaeve CM, Jager A, de Jongh FE, Hamberg P, van Galen A, Kraan J, Jansen MP, et al. An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. Bmc Cancer. 16: 123. PMID 26892682 DOI: 10.1186/S12885-016-2155-Y |
0.409 |
|
| 2016 |
Bartlett JM, Christiansen J, Gustavson M, Rimm DL, Piper T, de Velde CJ, Hasenburg A, Kieback DG, Putter H, Markopoulos CJ, Dirix LY, Seynaeve C, Rea DW. Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial. Archives of Pathology & Laboratory Medicine. 140: 66-74. PMID 26717057 DOI: 10.5858/arpa.2014-0599-OA |
0.326 |
|
| 2016 |
Rypens C, Marsan M, Neven P, Vermeulen PB, Lardon F, Peeters M, Dirix L, Vandebroek J, Van Laere SJ. Patterns of canonical and non-canonical TGFβ signaling in inflammatory breast cancer cells on cancer cell motility. Journal of Clinical Oncology. 34: e23008-e23008. DOI: 10.1200/Jco.2016.34.15_Suppl.E23008 |
0.456 |
|
| 2016 |
Dummer R, Migden MR, Guminski A, Gutzmer R, Kudchadkar RR, Lewis KD, Dirix L, Combemale P, Trefzer U, Loquai C, Kaatz M, Chang ALS, Stratigos A, Plummer ER, Mone M, et al. Efficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis. Journal of Clinical Oncology. 34: 9538-9538. DOI: 10.1200/Jco.2016.34.15_Suppl.9538 |
0.319 |
|
| 2016 |
Brufsky A, Kim S, Velu TJ, Saenz JAG, Tan-Chiu E, Sohn J, Dirix LY, Vanasek J, Borms MV, Mingorance JID, Liu M, Moezi MM, Kozloff M, Sparano JA, Hsu JJ, et al. Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study. Journal of Clinical Oncology. 34: 1074-1074. DOI: 10.1200/Jco.2016.34.15_Suppl.1074 |
0.366 |
|
| 2016 |
Dirix L, Takacs I, Nikolinakos P, Jerusalem G, Arkenau H, Hamilton E, Heydebreck Av, Grote H, Chin K, Lippman M. Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-S1-04 |
0.391 |
|
| 2016 |
Bardia A, Modi S, Oliveira M, Campone M, Ma B, Dirix L, Weise A, Nardi L, Zhang V, Bhansali S, Hewes B, Chavez-MacGregor M. Abstract P6-13-01: Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2– advanced breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-13-01 |
0.417 |
|
| 2016 |
Kaufman P, Arias-Pulido H, Colpaert C, Chaher N, Qualls C, Marotti J, Vermeulen P, Dirix L, Laere Sv, Kuppusamy P. Abstract P5-08-13: Tumor infiltrating lymphocytes and pathological response are prognostic biomarkers in inflammatory and non-inflammatory breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P5-08-13 |
0.499 |
|
| 2016 |
Brouwer A, Wiel Mvd, Peeters B, Dam Pv, Vermeulen P, Peeters M, Laere SV, Peeters D, Dirix L. Abstract P3-04-01: Manual and digital detection of HER2 status of 2721 circulating tumour cells in patients with metastatic breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-04-01 |
0.466 |
|
| 2016 |
Bayani J, Yao C, Quintayo M, Haider S, Brookes C, Yan F, Velde Cvd, Hasenburg A, Kieback D, Markopoulos C, Dirix L, Seynaeve C, Boutros P, Rea D, Bartlett J. Abstract P2-08-29: Defining a signature of residual risk following endocrine treatment in the tamoxifen and exemestane adjuvant multinational (TEAM) trial Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P2-08-29 |
0.389 |
|
| 2016 |
Bidard F, Peeters D, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz J, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, Lascoiti AFd, ... ... Dirix L, et al. Abstract P2-08-08: Circulating tumor cells count-based nomograms to predict survival of metastatic breast cancer patients: Results from the European pooled analysis Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P2-08-08 |
0.423 |
|
| 2016 |
Miles DW, Kim S, Velu T, García-Saenz JA, Tan-Chiu E, Sohn JH, Dirix L, Vanˇásek J, Borms MV, Mingorance JID, Liu M, Moezi MM, Kozloff MF, Sparano JA, Xu N, et al. First-line cobimetinib (C) + paclitaxel (P) in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and tumoral immune cell infiltration data from the phase 2 COLET study Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw365.65 |
0.458 |
|
| 2015 |
Tryfonidis K, Basaran G, Bogaerts J, Debled M, Dirix L, Thery JC, Tjan-Heijnen VC, Van den Weyngaert D, Cufer T, Piccart M, Cameron D. A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378). European Journal of Cancer (Oxford, England : 1990). 53: 144-154. PMID 26724641 DOI: 10.1016/J.Ejca.2015.10.012 |
0.445 |
|
| 2015 |
Teuwen L, Mooter TVd, Dirix L. Management of pulmonary toxicity associated with targeted anticancer therapies. Expert Opinion On Drug Metabolism & Toxicology. 11: 1695-1707. PMID 26293379 DOI: 10.1517/17425255.2015.1080687 |
0.308 |
|
| 2015 |
Pastushenko I, Vermeulen PB, Vicente-Arregui S, Van den Eynden GG, Alvarez-Alegret R, Querol I, Rutten A, Carapeto FJ, Dirix LY, Van Laere S. Peritumoral D2-40 Chalkley score independently predicts metastases and survival in patients with cutaneous malignant melanoma. Journal of Cutaneous Pathology. 42: 699-711. PMID 26264662 DOI: 10.1111/Cup.12571 |
0.333 |
|
| 2015 |
Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B, Dirix LY, van Soest RJ, Lolkema MP, Martens JW, van Weerden WM, Jenster GW, et al. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. European Urology. 68: 939-45. PMID 26188394 DOI: 10.1016/J.Eururo.2015.07.007 |
0.342 |
|
| 2015 |
Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. The Lancet. Oncology. 16: 716-28. PMID 25981810 DOI: 10.1016/S1470-2045(15)70100-2 |
0.357 |
|
| 2015 |
Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Dirix L, Hou J, Yue H, Hauschild A, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. Journal of the American Academy of Dermatology. 72: 1021-6.e8. PMID 25981002 DOI: 10.1016/J.Jaad.2015.03.021 |
0.301 |
|
| 2015 |
Bertucci F, Finetti P, Colpaert C, Mamessier E, Parizel M, Dirix L, Viens P, Birnbaum D, van Laere S. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget. 6: 13506-19. PMID 25940795 DOI: 10.18632/Oncotarget.3642 |
0.468 |
|
| 2015 |
Mooter TVd, Teuwen L, Rutten A, Dirix L. Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer Expert Opinion On Biological Therapy. 15: 749-760. PMID 25865453 DOI: 10.1517/14712598.2015.1036026 |
0.377 |
|
| 2015 |
Fontein DBY, Grand MK, Nortier JWR, Seynaeve C, Kranenbarg EM, Dirix LY, Velde CJHvd, Putter H. Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial Annals of Oncology. 26: 1254-1262. PMID 25862439 DOI: 10.1093/Annonc/Mdv146 |
0.404 |
|
| 2015 |
van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Research : Bcr. 17: 21. PMID 25849621 DOI: 10.1186/S13058-015-0526-Y |
0.355 |
|
| 2015 |
Onstenk W, Sieuwerts AM, Weekhout M, Mostert B, Reijm EA, Deurzen CHMv, Vries JBB, Peeters DJ, Hamberg P, Seynaeve C, Jager A, Jongh FEd, Smid M, Dirix LY, Kehrer DFS, et al. Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. Cancer Letters. 362: 36-44. PMID 25797316 DOI: 10.1016/J.Canlet.2015.03.020 |
0.407 |
|
| 2015 |
Jansen MP, Sas L, Sieuwerts AM, Van Cauwenberghe C, Ramirez-Ardila D, Look M, Ruigrok-Ritstier K, Finetti P, Bertucci F, Timmermans MM, van Deurzen CH, Martens JW, Simon I, Roepman P, Linn SC, ... ... Dirix L, et al. Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. Molecular Oncology. 9: 1218-33. PMID 25771305 DOI: 10.1016/J.Molonc.2015.02.006 |
0.462 |
|
| 2015 |
Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, Tsui V, Durham AB, Dlugosz AA, Haverty PM, Bourgon R, Tang JY, Sarin KY, Dirix L, Fisher DC, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 27: 327-41. PMID 25759019 DOI: 10.1016/J.Ccell.2015.02.001 |
0.334 |
|
| 2015 |
Diéras V, Wildiers H, Jassem J, Dirix LY, Guastalla JP, Bono P, Hurvitz SA, Gonçalves A, Romieu G, Limentani SA, Jerusalem G, Lakshmaiah KC, Roché H, Sánchez-Rovira P, Pienkowski T, et al. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. Breast (Edinburgh, Scotland). 24: 182-90. PMID 25747197 DOI: 10.1016/J.Breast.2014.11.003 |
0.385 |
|
| 2015 |
Krop IE, Suter TM, Dang CT, Dirix L, Romieu G, Zamagni C, Citron ML, Campone M, Xu N, Smitt M, Gianni L. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1136-42. PMID 25713436 DOI: 10.1200/Jco.2014.58.7782 |
0.435 |
|
| 2015 |
Mostert B, Sieuwerts AM, Kraan J, Vries JB, Spoel Pvd, Galen Av, Peeters DJ, Dirix LY, Seynaeve CM, Jager A, Jongh FEd, Hamberg P, Stouthard JML, Kehrer DFS, Look MP, et al. Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients Annals of Oncology. 26: 510-516. PMID 25471333 DOI: 10.1093/Annonc/Mdu557 |
0.426 |
|
| 2015 |
Peeters DJ, Brouwer A, Van den Eynden GG, Rutten A, Onstenk W, Sieuwerts AM, Van Laere SJ, Huget P, Pauwels P, Peeters M, Vermeulen PB, Dirix LY. Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer. Cancer Letters. 356: 872-9. PMID 25449778 DOI: 10.1016/J.Canlet.2014.10.039 |
0.471 |
|
| 2015 |
Spigel DR, Chaft JE, Gettinger SN, Chao BH, Dirix LY, Schmid P, Chow LQM, Chappey C, Kowanetz M, Sandler A, Funke RP, Rizvi NA. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 33: 8028-8028. DOI: 10.1200/Jco.2015.33.15_Suppl.8028 |
0.322 |
|
| 2015 |
De Laere B, Peeters DJE, Salgado R, Vermeulen PB, van Dam PA, Van Laere SJ, Dirix LY. Exploring the intra-patient PIK3CA mutational heterogeneity of circulating tumour cells by massive parallel sequencing in patients with metastatic hormone receptor-positive breast cancer. Journal of Clinical Oncology. 33: 11030-11030. DOI: 10.1200/Jco.2015.33.15_Suppl.11030 |
0.433 |
|
| 2015 |
Bartlett JM, Sabine VS, Haider S, Drake C, Crozier C, Yao CQ, Brookes CL, Velde CJvd, Hasenburg A, Kieback DG, Markopoulos C, Dirix LY, Seynaeve C, Rea DW, Boutros PC. Abstract S2-01: Theranostic multiparametric tests improve residual risk assessment in early luminal breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S2-01 |
0.45 |
|
| 2015 |
Evans MK, Sauer SJ, Aldrich AJ, Geradts J, Vermeulen P, Dirix L, Laere SV, Devi GR. Abstract P6-14-05: A novel link between anti-apoptotic signaling, NFκB, and SMAD7 in IBC pathobiology Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-14-05 |
0.419 |
|
| 2015 |
Stephen J, Murray G, Cameron D, Thomas J, Kunkler I, Jack W, Kerr G, Piper T, Brookes C, Rea D, Velde Cvd, Hasenburg A, Markopoulos C, Dirix L, Seynaeve C, et al. Abstract P4-11-10: Time dependence of biomarkers: Non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-11-10 |
0.448 |
|
| 2015 |
Stephen J, Murray G, Cameron D, Thomas J, Kunkler I, Jack W, Kerr G, Piper T, Brookes C, Rea D, Velde Cvd, Hasenburg A, Markopoulos C, Dirix L, Seynaeve C, et al. Abstract P4-11-09: Comparison of immunohistochemical residual risk panels to predict risk in early breast cancers treated with endocrine therapy Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-11-09 |
0.456 |
|
| 2015 |
Bartlett JM, Brookes CL, Yan FJ, Quintayo MA, Bayani J, Starczynski J, Velde CJvd, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Rea DW. Abstract P4-11-05: Does androgen receptor (AR) expression impact on residual risk? A TEAM pathology study Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-11-05 |
0.408 |
|
| 2015 |
Colpaert C, Marsan M, Vermeulen P, Dirix L, Laere SV. Abstract P4-04-20: Tumor infiltrating lymphocytes in inflammatory breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-04-20 |
0.495 |
|
| 2015 |
Peeters DJ, Beeck KOD, Brouwer A, Vandeweyer G, Pauwels P, Peeters M, Vermeulen PB, Dam PAv, Laere SJV, Camp GV, Dirix LY. Abstract P4-01-14: Whole exome sequencing of circulating and disseminated tumour cells in patients with metastatic breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-01-14 |
0.434 |
|
| 2015 |
Colpaert C, Marsan M, Vermeulen P, Dirix L, Laere SV. Abstract P3-06-39: Anaplastic lymphoma kinase (ALK) protein overexpression is not a feature of inflammatory breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-39 |
0.433 |
|
| 2015 |
Marsan M, Eynden GVd, Neven P, Vergote I, Vermeulen P, Dirix L, Laere SV. Abstract P1-07-09: SMAD nuclear staining patterns in inflammatory breast cancer suggest non-canonical TGFβ-signalling establishing collective, sheet-like invasion SMAD nuclear staining patterns in inflammatory breast cancer suggest non-canonical TGFβ-signalling es Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P1-07-09 |
0.47 |
|
| 2015 |
Martín M, Chan A, Dirix L, O'Shaughnessy J, Hegg R, Manikhas A, Shtivelband M, Krivorotko P, López NB, Campone M, Borrego MR, Khan QJ, Beck JT, Vasquez MR, Urban P, et al. Abstract A166: BELLE-4: A Phase II study of buparlisib and paclitaxel in women with HER2- advanced breast cancer, with or without PI3K pathway activation Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A166 |
0.42 |
|
| 2015 |
Colpaert CG, Marsan M, Eynden GVd, Vermeulen P, Dirix LY, Laere SV. 76PTumour infiltrating lymphocytes in inflammatory breast cancer Annals of Oncology. 26. DOI: 10.1093/Annonc/Mdv118.02 |
0.436 |
|
| 2015 |
Peeters D, Brouwer A, Op de Beeck K, Van de Weyer G, Pauwels P, Peeters M, Vermeulen P, Van Laere S, Van Camp G, Dirix L. Whole exome sequencing of circulating and disseminated tumour cells in patients with metastatic breast cancer Annals of Oncology. 26: iii10. DOI: 10.1093/Annonc/Mdv116.04 |
0.472 |
|
| 2015 |
Onstenk W, Sieuwerts A, Kraan J, Van M, Nieuweboer A, Mathijssen R, Hamberg P, Meulenbeld H, DeLaere B, Dirix L, Soest RV, Lolkema M, Martens J, Weerden WV, Jenster G, et al. 2575 Presence of androgen receptor splice variants in circulating tumor cells and response to cabazitaxel in castration-resistant prostate cancer European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31394-6 |
0.318 |
|
| 2015 |
Chi K, Castellano D, Bono JD, Gravis G, Dirix L, Machiels JP, Mita A, Gonzalez BM, Massard C, Trandafir L, Dey D, Csonka D, Chakravartty A, Fizazi K. 2550 Phase Ib study of abiraterone acetate (AA) plus buparlisib (BKM120) or BEZ235 in patients (pts) with castration-resistant prostate cancer (CRPC) European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31369-7 |
0.33 |
|
| 2015 |
Beije N, Onstenk W, Kraan J, Hamberg AP, Dirix LY, Peeters DJ, Jongh FED, Jager A, Seynaeve CM, Van NM, Martens JWM, Sleijfer S. 1883 Prevalence and prognostic impact of HER2-positive circulating tumor cells in metastatic breast cancer patients with HER2-negative primary tumors European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)30833-4 |
0.448 |
|
| 2014 |
Chu QS, Mahipal A, Schuler M, De Braud FG, Dirix L, Rampersad A, Zhou J, Wu Y, Kalambakas S, Wen PY. 445ODOSE-ESCALATION STUDY OF SONIDEGIB (LDE225) PLUS BUPARLISIB (BKM120) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv147-iv148. PMID 28170893 DOI: 10.1093/Annonc/Mdu331.5 |
0.337 |
|
| 2014 |
Limame R, de Beeck KO, Van Laere S, Croes L, De Wilde A, Dirix L, Van Camp G, Peeters M, De Wever O, Lardon F, Pauwels P. Expression profiling of migrated and invaded breast cancer cells predicts early metastatic relapse and reveals Krüppel-like factor 9 as a potential suppressor of invasive growth in breast cancer. Oncoscience. 1: 69-81. PMID 25593984 DOI: 10.18632/ONCOSCIENCE.10 |
0.345 |
|
| 2014 |
Stephen J, Murray G, Cameron DA, Thomas J, Kunkler IH, Jack W, Kerr GR, Piper T, Brookes CL, Rea DW, van de Velde CJ, Hasenburg A, Markopoulos C, Dirix L, Seynaeve C, et al. Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer. British Journal of Cancer. 111: 2242-7. PMID 25314051 DOI: 10.1038/Bjc.2014.530 |
0.393 |
|
| 2014 |
Dirix LY, Reynolds AR. Bevacizumab beyond progression in breast cancer. Lancet Oncology. 15: 1190-1191. PMID 25273341 DOI: 10.1016/S1470-2045(14)70454-1 |
0.467 |
|
| 2014 |
Sabine VS, Crozier C, Brookes CL, Drake C, Piper T, Velde CJHvd, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Rea DW, Bartlett JMS. Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study Journal of Clinical Oncology. 32: 2951-2958. PMID 25071141 DOI: 10.1200/Jco.2013.53.8272 |
0.313 |
|
| 2014 |
Vergote I, Schilder RJ, Pippitt CH, Wong S, Gordon AN, Scudder S, Kridelka F, Dirix L, Leach JW, Ananda S, Nanayakkara N, Melara R, Bass MB, Litten J, Adewoye H, et al. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Gynecologic Oncology. 135: 25-33. PMID 25019569 DOI: 10.1016/J.Ygyno.2014.07.003 |
0.325 |
|
| 2014 |
Bertucci F, Finetti P, Vermeulen P, Van Dam P, Dirix L, Birnbaum D, Viens P, Van Laere S. Genomic profiling of inflammatory breast cancer: a review. Breast (Edinburgh, Scotland). 23: 538-45. PMID 24998451 DOI: 10.1016/J.Breast.2014.06.008 |
0.434 |
|
| 2014 |
Pastushenko I, Vermeulen PB, Van den Eynden GG, Rutten A, Carapeto FJ, Dirix LY, Van Laere S. Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications. The British Journal of Dermatology. 171: 220-33. PMID 24641095 DOI: 10.1111/Bjd.12973 |
0.341 |
|
| 2014 |
Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, ... ... Dirix L, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. The Lancet. Oncology. 15: 406-14. PMID 24636208 DOI: 10.1016/S1470-2045(14)70069-5 |
0.48 |
|
| 2014 |
Marsan M, Van den Eynden G, Limame R, Neven P, Hauspy J, Van Dam PA, Vergote I, Dirix LY, Vermeulen PB, Van Laere SJ. A core invasiveness gene signature reflects epithelial-to-mesenchymal transition but not metastatic potential in breast cancer cell lines and tissue samples. Plos One. 9: e89262. PMID 24586640 DOI: 10.1371/Journal.Pone.0089262 |
0.462 |
|
| 2014 |
Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, et al. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2192-204. PMID 24563479 DOI: 10.1158/1078-0432.Ccr-13-2200 |
0.38 |
|
| 2014 |
Dirix L. Discovery and Exploitation of Novel Targets by Approved Drugs Journal of Clinical Oncology. 32: 720-721. PMID 24493724 DOI: 10.1200/Jco.2013.53.7118 |
0.361 |
|
| 2014 |
Saura C, Bendell J, Jerusalem G, Su S, Ru Q, De Buck S, Mills D, Ruquet S, Bosch A, Urruticoechea A, Beck JT, Di Tomaso E, Sternberg DW, Massacesi C, Hirawat S, ... Dirix L, et al. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1935-45. PMID 24470511 DOI: 10.1158/1078-0432.Ccr-13-1070 |
0.465 |
|
| 2014 |
Liu NQ, Stingl C, Look MP, Smid M, Braakman RB, De Marchi T, Sieuwerts AM, Span PN, Sweep FC, Linderholm BK, Mangia A, Paradiso A, Dirix LY, Van Laere SJ, Luider TM, et al. Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer. Journal of the National Cancer Institute. 106: djt376. PMID 24399849 DOI: 10.1093/Jnci/Djt376 |
0.467 |
|
| 2014 |
Peeters DJ, van Dam PJ, Van den Eynden GG, Rutten A, Wuyts H, Pouillon L, Peeters M, Pauwels P, Van Laere SJ, van Dam PA, Vermeulen PB, Dirix LY. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. British Journal of Cancer. 110: 375-83. PMID 24366294 DOI: 10.1038/Bjc.2013.743 |
0.499 |
|
| 2014 |
Bertucci F, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, Van Dam P, Woodward WA, Cristofanilli M, Reuben JM, Dirix L, et al. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 358-65. PMID 24299959 DOI: 10.1093/Annonc/Mdt496 |
0.448 |
|
| 2014 |
Pastushenko I, Vermeulen PB, Carapeto FJ, Van den Eynden G, Rutten A, Ara M, Dirix LY, Van Laere S. Blood microvessel density, lymphatic microvessel density and lymphatic invasion in predicting melanoma metastases: systematic review and meta-analysis. The British Journal of Dermatology. 170: 66-77. PMID 24134623 DOI: 10.1111/Bjd.12688 |
0.331 |
|
| 2014 |
Senkus E, Gomez H, Dirix L, Jerusalem G, Murray E, Van Tienhoven G, Westenberg AH, Bottomley A, Rapion J, Bogaerts J, Di Leo A, Nešković-Konstantinović Z. Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98. Psycho-Oncology. 23: 173-82. PMID 24038775 DOI: 10.1002/Pon.3384 |
0.437 |
|
| 2014 |
Sas L, Vermeulen PB, van Dam P, Dirix LY, Lardon F, Van Laere SJ. Contribution of ER and NF-κB to endocrine resistance in inflammatory breast cancer Breast Cancer Management. 3: 53-61. DOI: 10.2217/Bmt.13.72 |
0.47 |
|
| 2014 |
Sekulic A, Hainsworth JD, Lewis KD, Oro AE, Gesierich A, Mortier L, Dirix L, Bernard S, Dreno B, Murrell DF, Williams S, Hou J, Fisher DC, Hauschild A. Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression. Journal of Clinical Oncology. 32: 9081-9081. DOI: 10.1200/Jco.2014.32.15_Suppl.9081 |
0.322 |
|
| 2014 |
Lewis KD, Sekulic A, Hauschild A, Migden MR, Oro AE, LoRusso P, Rudin CM, Dirix L, Solomon JA, Hainsworth JD, Williams S, Hou J, Von Hoff DD. Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies. Journal of Clinical Oncology. 32: 9012-9012. DOI: 10.1200/Jco.2014.32.15_Suppl.9012 |
0.348 |
|
| 2014 |
Migden MR, Guminski AD, Gutzmer R, Dirix LY, Lewis KD, Combemale P, Herd R, Gogov S, Yi T, Mone M, Kudchadkar RR, Trefzer U, Lear J, Sellami DB, Dummer R. Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal-cell carcinoma (BCC) Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.9009A |
0.326 |
|
| 2014 |
Zambrano CC, Schuler MH, Machiels JH, Hess D, Paz-Ares L, Awada A, Moos Rv, Steeghs N, Ahnert JR, Mesmaeker PD, Richly H, Herremans C, Joerger M, Jaime JC, Alsina M, ... ... Dirix L, et al. Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC). Journal of Clinical Oncology. 32: 627-627. DOI: 10.1200/Jco.2014.32.15_Suppl.627 |
0.348 |
|
| 2014 |
Ahnert JR, Schuler MH, Machiels JH, Hess D, Paz-Ares L, Awada A, Moos Rv, Steeghs N, Zambrano CC, Mesmaeker PD, Richly H, Herremans C, Joerger M, Jaime JC, Alsina M, ... ... Dirix L, et al. Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC). Journal of Clinical Oncology. 32: 621-621. DOI: 10.1200/Jco.2014.32.15_Suppl.621 |
0.36 |
|
| 2014 |
Im S, Juric D, Baselga J, Kong A, Martin P, Lin C, Dees EC, Schellens JHM, De Braud FG, Delgado L, Zucchetto M, Tian X, Fernandez R, Morozov A, Dirix LY. A phase 1 dose-escalation study of anti-HER3 monoclonal antibody LJM716 in combination with trastuzumab in patients with HER2-overexpressing metastatic breast or gastric cancer. Journal of Clinical Oncology. 32: 2519-2519. DOI: 10.1200/Jco.2014.32.15_Suppl.2519 |
0.435 |
|
| 2014 |
Onstenk W, Sieuwerts AM, Weekhout M, Mostert B, Reijm EA, Deurzen CHMV, Kraan J, Jager A, Seynaeve C, Peeters D, Hamberg P, Jongh FEd, Galen AMv, Moreno RR, Smid M, ... Dirix L, et al. Gene expression profiles of primary tumors versus circulating tumor cells in metastatic breast cancer. Journal of Clinical Oncology. 32: 11017-11017. DOI: 10.1200/Jco.2014.32.15_Suppl.11017 |
0.432 |
|
| 2014 |
Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis K, Combemale P, Herd R, Kaatz M, Loquai C, Stratigos A, Schulze H, Plummer R, Yi T, Chang ALS, Cornélis F, et al. Lba33Randomized, Double-Blind Study Of Sonidegib (Lde225) In Patients (Pts) With Advanced Basal Cell Carcinoma (Bcc) Annals of Oncology. 25. DOI: 10.1093/Annonc/Mdu438.41 |
0.319 |
|
| 2014 |
Bardia A, Chavez-MacGregor C, Modi S, Campone M, Ma B, Kittaneh M, Dirix L, Motta M, Zhang V, Bhansali S, Fjaellskog ML, Oliveira M. 500 Triple blockade with LEE011, everolimus, and exemestane in women with ER+/HER2− advanced/metastatic breast cancer: results from a Phase Ib clinical trial European Journal of Cancer. 50: 163. DOI: 10.1016/S0959-8049(14)70626-4 |
0.432 |
|
| 2013 |
Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, Kai K, Kogawa T, Finetti P, Birnbaum D, Dirix L, Woodward WA, Reuben JM, Krishnamurthy S, Symmans W, et al. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Research : Bcr. 15: R112. PMID 24274653 DOI: 10.1186/Bcr3579 |
0.46 |
|
| 2013 |
Jansen MP, Knijnenburg T, Reijm EA, Simon I, Kerkhoven R, Droog M, Velds A, van Laere S, Dirix L, Alexi X, Foekens JA, Wessels L, Linn SC, Berns EM, Zwart W. Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer. Cancer Research. 73: 6632-41. PMID 24242068 DOI: 10.1158/0008-5472.Can-13-0704 |
0.459 |
|
| 2013 |
Vergote IB, Garcia A, Micha J, Pippitt C, Bendell J, Spitz D, Reed N, Dark G, Fracasso PM, Ibrahim EN, Armenio VA, Duska L, Poole C, Gennigens C, Dirix LY, et al. Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4060-6. PMID 24081946 DOI: 10.1200/Jco.2012.45.1278 |
0.338 |
|
| 2013 |
Ramirez-Ardila DE, Helmijr JC, Look MP, Lurkin I, Ruigrok-Ritstier K, van Laere S, Dirix L, Sweep FC, Span PN, Linn SC, Foekens JA, Sleijfer S, Berns EM, Jansen MP. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Research and Treatment. 139: 39-49. PMID 23592373 DOI: 10.1007/S10549-013-2529-7 |
0.354 |
|
| 2013 |
Woodward WA, Krishnamurthy S, Yamauchi H, El-Zein R, Ogura D, Kitadai E, Niwa SI, Cristofanilli M, Vermeulen P, Dirix L, Viens P, Van Laere S, Bertucci F, Reuben JM, Ueno NT. Genomic and expression analysis of microdissected inflammatory breast cancer Breast Cancer Research and Treatment. 138: 761-772. PMID 23568481 DOI: 10.1007/S10549-013-2501-6 |
0.352 |
|
| 2013 |
van Dam PA, Verheyden G, Sugihara A, Trinh XB, Van Der Mussele H, Wuyts H, Verkinderen L, Hauspy J, Vermeulen P, Dirix L. A dynamic clinical pathway for the treatment of patients with early breast cancer is a tool for better cancer care: implementation and prospective analysis between 2002-2010. World Journal of Surgical Oncology. 11: 70. PMID 23497270 DOI: 10.1186/1477-7819-11-70 |
0.392 |
|
| 2013 |
Dirix LY, Rutten A, Huget P, Dirix M. Trastuzumab emtansine in breast cancer. Expert Opinion On Biological Therapy. 13: 607-614. PMID 23477731 DOI: 10.1517/14712598.2013.778238 |
0.378 |
|
| 2013 |
Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR, Scherer SJ. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. British Journal of Cancer. 108: 1052-60. PMID 23422754 DOI: 10.1038/Bjc.2013.69 |
0.461 |
|
| 2013 |
Van Laere SJ, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, van Dam P, Woodward WA, Viens P, Cristofanilli M, Birnbaum D, ... Dirix L, et al. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4685-96. PMID 23396049 DOI: 10.1158/1078-0432.Ccr-12-2549 |
0.445 |
|
| 2013 |
Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1157-63. PMID 23382472 DOI: 10.1200/Jco.2012.44.9694 |
0.472 |
|
| 2013 |
Lehman HL, Dashner EJ, Lucey M, Vermeulen P, Dirix L, Van Laere S, van Golen KL. Modeling and characterization of inflammatory breast cancer emboli grown in vitro. International Journal of Cancer. 132: 2283-94. PMID 23129218 DOI: 10.1002/Ijc.27928 |
0.443 |
|
| 2013 |
Awada A, Dirix L, Manso Sanchez L, Xu B, Luu T, Diéras V, Hershman DL, Agrapart V, Ananthakrishnan R, Staroslawska E. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 109-16. PMID 22967996 DOI: 10.1093/Annonc/Mds284 |
0.494 |
|
| 2013 |
Water Wvd, Fontein DBY, Nes JGHv, Bartlett JMS, Hille ETM, Putter H, Robson T, Liefers G, Roumen RMH, Seynaeve C, Dirix LY, Paridaens R, Kranenbarg EM, Nortier JWR, Velde CJHvd. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer – A TEAM study analysis European Journal of Cancer. 49: 297-304. PMID 22954666 DOI: 10.1016/J.Ejca.2012.07.026 |
0.432 |
|
| 2013 |
Reijm EA, Sieuwerts AM, Vries JB, Mostert B, Onstenk W, Peeters D, Dirix LY, Seynaeve C, Jager A, Jongh FEd, Hamberg P, Galen AMv, Kraan J, Jansen MPHM, Gratama J, et al. mRNA expression profiles in circulating tumor cells (CTCs) of patients with metastatic breast cancer (MBC) treated with aromatase inhibitors (AI). Journal of Clinical Oncology. 31: 11045-11045. DOI: 10.1200/Jco.2013.31.15_Suppl.11045 |
0.44 |
|
| 2013 |
Sas L, Dam PV, Dirix L, Vermeulen P, Lardon F, Laere SV. Abstract 99: Identification of genes involved in NFκB driven resistance to endocrine treatment in breast cancer. Endocrinology. 73: 99-99. DOI: 10.1158/1538-7445.Am2013-99 |
0.428 |
|
| 2013 |
Limame R, Beeck KOd, Laere SV, Camp GV, Peeters M, Dirix L, Lardon F, Wever OD, Pauwels P. Abstract 2633: Gene signatures derived from in vitro isolated migratory and invasive breast cancer cells indicate early metastatic relapse. Cancer Research. 73: 2633-2633. DOI: 10.1158/1538-7445.Am2013-2633 |
0.467 |
|
| 2013 |
Bidard F, Peeters D, Fehm T, Nole F, Gisbert-Criado R, Mavrudis D, Grisanti S, Generali D, Garcia-Saenz J, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, Antelo M, ... ... Dirix L, et al. Abstract PD6-5: Pooled analysis of circulating tumor cells in metastatic breast cancer: Findings from 1944 individual patients data Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Pd6-5 |
0.462 |
|
| 2013 |
Joglekar M, Laere SV, Vermeulen P, Dirix L, Carter M, Rhamchandran A, Golen Kv. Abstract P6-12-15: Preclinical testing of a novel platelet derived growth factor receptor alpha (PDGFRa) inhibitor in inflammatory breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P6-12-15 |
0.465 |
|
| 2013 |
Sas L, Dirix L, Vermeulen P, Dam PV, Lardon F, Laere SV. Abstract P5-09-04: The effect of nuclear factor kappa B activation on cell proliferation of estrogen receptor positive breast cancer cell lines with different HER2-status Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P5-09-04 |
0.427 |
|
| 2013 |
Krop I, Suter T, Dirix L, Romieu G, Zamagni C, Citron M, Campone M, Dang C, Xu N, Smitt M, Gianni L. Abstract P2-15-03: Cardiac safety of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (EBC): Final data from TDM4874g Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P2-15-03 |
0.344 |
|
| 2013 |
Laere SV, Marsan M, Vermeulen P, Viens P, Barsky S, Cristofanilli M, Dirix L, Bertucci F, Robertson F. Abstract P2-05-04: Comparative expression profiling of patient samples and preclinical models of inflammatory breast cancer reveals gene signatures of epithelial plasticity and suppression of TGFb signaling Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P2-05-04 |
0.414 |
|
| 2013 |
Laere BD, Peeters D, Schooneveld Ev, Salgado R, Vermeulen P, Dirix L, Laere SV. Abstract P1-04-04: Towards methodology of detecting PIK3CA mutations on single cell level by massive parallel sequencing Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P1-04-04 |
0.406 |
|
| 2013 |
Peeters D, Kumar P, Aa NVd, Rothé F, Theunis K, Beeck KOd, Laere SV, Vermeulen P, Dam Pv, Vincent D, Desmedt C, Sotiriou C, Dirix L, Ignatiadis M, Voet T. Abstract P1-04-03: Genome-wide analysis of copy number variations and mutation profiles of single circulating tumour cells using massively parallel paired-end sequencing Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P1-04-03 |
0.348 |
|
| 2013 |
Martin M, Batista N, Shtivelband M, Chan A, Delaloge S, Dirix L, Lee S, Mouhaer SL, Nanni S, DiTomaso E, Urban P, O'Shaughnessy J. Abstract OT2-6-07: Buparlisib (BKM120), an oral pan-PI3K inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer, with or without PI3K pathway activation: A phase II, randomized, double-blind, placebo-controlled study – BELLE-4 Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Ot2-6-07 |
0.457 |
|
| 2012 |
Cardoso F, Canon JL, Amadori D, Aldrighetti D, Machiels JP, Bouko Y, Verkh L, Usari T, Kern KA, Giorgetti C, Dirix L. An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. The Breast. 21: 716-723. PMID 23022045 DOI: 10.1016/J.Breast.2012.09.002 |
0.478 |
|
| 2012 |
Sas L, Lardon F, Vermeulen PB, Hauspy J, Van Dam P, Pauwels P, Dirix LY, Van Laere SJ. The interaction between ER and NFκB in resistance to endocrine therapy. Breast Cancer Research : Bcr. 14: 212. PMID 22963717 DOI: 10.1186/Bcr3196 |
0.418 |
|
| 2012 |
Lehman HL, Van Laere SJ, van Golen CM, Vermeulen PB, Dirix LY, van Golen KL. Regulation of inflammatory breast cancer cell invasion through Akt1/PKBα phosphorylation of RhoC GTPase. Molecular Cancer Research : McR. 10: 1306-18. PMID 22896661 DOI: 10.1158/1541-7786.Mcr-12-0173 |
0.471 |
|
| 2012 |
Dirix L, Rutten A. Vismodegib: a promising drug in the treatment of basal cell carcinomas Future Oncology. 8: 915-928. PMID 22894666 DOI: 10.2217/Fon.12.82 |
0.362 |
|
| 2012 |
Fontein DBY, Houtsma D, Hille ETM, Seynaeve C, Putter H, Kranenbarg EM, Guchelaar HJ, Gelderblom H, Dirix LY, Paridaens R, Bartlett JMS, Nortier JWR, Velde CJHvd. Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients Annals of Oncology. 23: 3091-3097. PMID 22865782 DOI: 10.1093/Annonc/Mds204 |
0.431 |
|
| 2012 |
Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, et al. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment. 134: 1149-59. PMID 22763464 DOI: 10.1007/S10549-012-2126-1 |
0.516 |
|
| 2012 |
Rini B, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Dirix LY, Fishman M, Ramlau R, Ravaud A, Rogowski W, Kracht K, Sun YN, Bass MB, Puhlmann M, et al. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer. 118: 6152-61. PMID 22692704 DOI: 10.1002/Cncr.27632 |
0.365 |
|
| 2012 |
Dirix LY, Vermeulen PB. Inflammatory HER2-positive breast cancer. The Lancet. Oncology. 13: 324-6. PMID 22377127 DOI: 10.1016/S1470-2045(12)70081-5 |
0.437 |
|
| 2012 |
van Schooneveld E, Wouters MC, Van der Auwera I, Peeters DJ, Wildiers H, Van Dam PA, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Research : Bcr. 14: R34. PMID 22353773 DOI: 10.1186/Bcr3127 |
0.39 |
|
| 2012 |
Trinh XB, Sas L, Van Laere SJ, Prové A, Deleu I, Rasschaert M, Van de Velde H, Vinken P, Vermeulen PB, Van Dam PA, Wojtasik A, De Mesmaeker P, Tjalma WA, Dirix LY. A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer. Oncology Reports. 27: 657-63. PMID 22134540 DOI: 10.1158/0008-5472.Sabcs-09-4099 |
0.49 |
|
| 2012 |
Thertulien R, Manikhas GM, Dirix LY, Vermorken JB, Park K, Jain MM, Jiao JJ, Natarajan J, Parekh T, Zannikos P, Staddon AP. Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies Cancer Chemotherapy and Pharmacology. 69: 341-350. PMID 21739119 DOI: 10.1007/S00280-011-1697-6 |
0.377 |
|
| 2012 |
Sekulic A, Migden MR, Oro AE, Lewis KD, Hainsworth JD, Yoo S, Dirix L, Hou J, Yue H, Hauschild A. Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update. Journal of Clinical Oncology. 30: 8579-8579. DOI: 10.1200/Jco.2012.30.15_Suppl.8579 |
0.302 |
|
| 2012 |
Dang CT, Gianni L, Romieu G, Dirix L, Campone M, Citron ML, Zamagni C, Krop IE, Xu N, Smitt M, Suter T. Cardiac safety in a phase II study of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancer. Journal of Clinical Oncology. 30: 532-532. DOI: 10.1200/Jco.2012.30.15_Suppl.532 |
0.417 |
|
| 2012 |
Christiansen J, Bartlett JMS, Gustavson M, Rimm D, Robson T, Velde CJHVD, Hasenburg A, Kieback DG, Putter H, Markopoulos C, Dirix LY, Seynaeve CM, Rea D. Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches Journal of Clinical Oncology. 30: 517-517. DOI: 10.1200/Jco.2012.30.15_Suppl.517 |
0.383 |
|
| 2012 |
Bartlett JMS, Bloom KJ, Robson T, Lawton TJ, Velde CJHVD, Ross DT, Seitz RS, Beck RA, Hasenburg A, Kieback DG, Putter H, Markopoulos C, Dirix LY, Seynaeve CM, Rea D. Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the TEAM pathology study. Journal of Clinical Oncology. 30: 516-516. DOI: 10.1200/Jco.2012.30.15_Suppl.516 |
0.408 |
|
| 2012 |
Mostert B, Sieuwerts AM, Kraan J, Vries JB, Peeters D, Dirix L, Seynaeve CM, Jager A, Jongh FEd, Hamberg P, Stouthard J, Kehrer DFS, Look MP, Smid M, Jiang Y, et al. Gene expression profiles of circulating tumor cells in metastatic breast cancer patients. Journal of Clinical Oncology. 30: 10504-10504. DOI: 10.1200/Jco.2012.30.15_Suppl.10504 |
0.497 |
|
| 2012 |
Laere SJV, Jansen MP, Sas L, Sieuwerts A, Vermeulen PB, Berns EM, Dirix LY. Abstract 684: Identification of biomarker genes associated with endocrine therapy responsiveness in patients with estrogen receptor positive IBC and nIBC Cancer Research. 72: 684-684. DOI: 10.1158/1538-7445.Am2012-684 |
0.453 |
|
| 2012 |
Limame R, Laere SV, Beeck KOD, Camp GV, Vermeulen P, Dirix L, Peeters M, Pauwels P, Wever OD, Lardon F. Abstract 4319: Gene expression profiling of isolated small migratory and invasive breast cancer cells at different times during chemotaxis Cancer Research. 72: 4319-4319. DOI: 10.1158/1538-7445.Am2012-4319 |
0.44 |
|
| 2012 |
Peeters DJ, Eynden GGVd, Laere SJV, Salgado R, Huget P, Dam PAv, Peeters M, Pauwels P, Vermeulen PB, Dirix LY. Abstract 4072: Molecular characterization of single tumor cells isolated from blood samples using immunomagnetic enrichment and dielectrophoretic cell sorting: A feasibility study Cancer Research. 72: 4072-4072. DOI: 10.1158/1538-7445.Am2012-4072 |
0.399 |
|
| 2012 |
Sas L, Laere SV, Peeters D, Marsan M, Schooneveld Ev, Lardon F, Dam Pv, Dirix L, Vermeulen P. Abstract 3919: Novel model to study NFkB driven resistance to endocrine treatment in breast cancer Cancer Research. 72: 3919-3919. DOI: 10.1158/1538-7445.Am2012-3919 |
0.414 |
|
| 2012 |
Lehman H, Daasner E, Vermeulen P, Dirix L, Laere SV, Golen Kv. Abstract P3-10-08: A new in vitro method of growing and studying inflammatory breast cancer emboli Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P3-10-08 |
0.452 |
|
| 2012 |
Lehman H, Laere SV, Golen Cv, Vermeulen P, Dirix L, Golen Kv. Abstract P3-10-04: Regulation of inflammatory breast cancer cell invasion through Akt1/PKBα phosphorylation of RhoC GTPase Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P3-10-04 |
0.495 |
|
| 2012 |
Peeters D, Eynden GVd, Rutten A, Onstenk W, Sieuwerts A, Laere BD, Dam Pv, Peeters M, Pauwels P, Laere SV, Vermeulen P, Dirix L. Abstract P2-01-09: Tumor cell emboli in the lung and transcriptional profiles of circulating tumor cells derived from different vascular compartments in patients with metastatic breast cancer. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P2-01-09 |
0.454 |
|
| 2012 |
Peeters D, Dam Pv, Wuyts H, Eynden GVd, Jeuris K, Prové A, Rutten A, Peeters M, Pauwels P, Laere SV, Hauspy J, Dam Pv, Vermeulen P, Dirix L. Abstract P2-01-08: Different numbers and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P2-01-08 |
0.506 |
|
| 2012 |
Water Wvd, Fontein DBY, Bartlett JMS, Putter H, Robson T, Seynaeve C, Dirix LY, Kranenbarg EM, Nortier JWR, Velde CJHvd. 421 ER Allred Score Predicts Outcome of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer – a TEAM Study Analysis European Journal of Cancer. 48. DOI: 10.1016/S0959-8049(12)70487-2 |
0.422 |
|
| 2012 |
Fontein D, Houtsma D, Hille ETM, Kranenbarg WMM, Putter H, Seynaeve C, Dirix LY, Paridaens R, Velde CJHvd, Nortier JWR. 198 Specific Adverse Events Predict Survival Benefit in Early Breast Cancer Patients Treated with Exemestane in the Dutch/Belgian TEAM Trial European Journal of Cancer. 48. DOI: 10.1016/S0959-8049(12)70266-6 |
0.458 |
|
| 2012 |
Sekulic A, Migden M, Oro A, Lewis K, Hainsworth J, Yoo S, Dirix L, Hou J, Yue H, Hauschild A. Efficacy and Safety of the Hedgehog Pathway Inhibitor Vismodegib in Patients with Advanced Basal Cell Carcinoma (BCC): 12-Month Erivance BCC Study Update Annals of Oncology. 23: ix362. DOI: 10.1016/S0923-7534(20)33694-2 |
0.315 |
|
| 2012 |
Dirix L, Schuler M, Machiels J, Hess D, Awada A, Steeghs N, Paz-Ares L, Moos Rv, Rabault B, Rodon J. Phase IB Dose-Escalation Study of BEZ235 or BKM120 in Combination with Paclitaxel (PTX) in Patients With Advanced Solid Tumors Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)33012-X |
0.33 |
|
| 2012 |
Smit WM, Šufliarsky J, Werner TL, Dizon DS, Wagnerová M, Hirte HW, Spirtos NM, Oza A, Dirix L, El-Hashimy M, Acharyya S, Tan EY, Weber D, Schellens JHM. A phase II study of patupilone (EPO906) in patients with platinum-resistant or platinum-refractory ovarian cancer Clinical Ovarian and Other Gynecologic Cancer. 5: 53-59. DOI: 10.1016/J.Cogc.2012.06.001 |
0.415 |
|
| 2011 |
Garcia AA, Vergote IB, Micha JP, Pippitt CH, Rao GG, Spitz DL, Reed N, Dark GG, Ibrahim EN, Armenio VA, Duska LR, Poole CJ, Gennigens C, Dirix LY, West J, et al. The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 5047. PMID 28023700 DOI: 10.1200/Jco.2011.29.15_Suppl.5047 |
0.336 |
|
| 2011 |
Van Laere SJ, Ueno NT, Finetti P, Vermeulen PB, Lucci A, Birnbaum D, Robertson F, Iwamoto T, van Dam PA, Woodward WA, Viens P, Dirix LY, Reuben JM, Bertucci F. An integrated analysis of three distinct IBC/non-IBC affymetrix gene expression data sets to study the transcriptional heterogeneity both between IBC and non-IBC and within IBC. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10571. PMID 28021912 DOI: 10.1200/Jco.2011.29.15_Suppl.10571 |
0.354 |
|
| 2011 |
Dieras V, Jassem J, Dirix LY, Guastalla JP, Bono P, Hurvitz SA, Gonçalves A, Romieu G, Limentani SA, Jerusalem GH, Lakshmaiah K, Roche HH, Sánchez-Rovira P, Pienkowski T, Seguí-Palmer MA, et al. A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 544. PMID 28021511 DOI: 10.1200/Jco.2011.29.15_Suppl.544 |
0.431 |
|
| 2011 |
Trinh XB, van Dam PA, Vermeulen PB, Van Laere SJ, Van den Eynden GG, Tjalma WA, Dirix LY. VEGF-A-independent and angiogenesis-dependent tumour growth in patients with metastatic breast cancer. Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 13: 805-8. PMID 22082645 DOI: 10.1007/S12094-011-0737-3 |
0.43 |
|
| 2011 |
Tabernero J, Dirix L, Schöffski P, Cervantes A, Lopez-Martin JA, Capdevila J, Beijsterveldt Lv, Platero S, Hall B, Yuan Z, Knoblauch R, Zhuang SH. A Phase I First-In-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan In Patients With Advanced Solid Tumors Clinical Cancer Research. 17: 6313-6321. PMID 21831953 DOI: 10.1158/1078-0432.Ccr-11-1101 |
0.387 |
|
| 2011 |
Trinh XB, Tjalma WA, Dirix LY, Vermeulen PB, Peeters DJ, Bachvarov D, Plante M, Berns EM, Helleman J, Van Laere SJ, van Dam PA. Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma. Plos One. 6: e22469. PMID 21799864 DOI: 10.1371/Journal.Pone.0022469 |
0.378 |
|
| 2011 |
Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, Stouthard JM, Dirix LY, van Dam PA, Van Galen A, de Weerd V, Kraan J, van der Spoel P, Ramírez-Moreno R, van Deurzen CH, Smid M, et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3600-18. PMID 21505063 DOI: 10.1158/1078-0432.Ccr-11-0255 |
0.429 |
|
| 2011 |
Peeters DJ, Van den Eynden GG, van Dam PJ, Prové A, Benoy IH, van Dam PA, Vermeulen PB, Pauwels P, Peeters M, Van Laere SJ, Dirix LY. Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer. British Journal of Cancer. 104: 1472-7. PMID 21468046 DOI: 10.1038/Bjc.2011.122 |
0.487 |
|
| 2011 |
Bartlett JMS, Brookes CL, Robson T, Velde CJHvd, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ETM, Kay C, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, ... Dirix L, et al. Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial Journal of Clinical Oncology. 29: 1531-1538. PMID 21422407 DOI: 10.1200/Jco.2010.30.3677 |
0.413 |
|
| 2011 |
Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1147-59. PMID 21220480 DOI: 10.1158/1078-0432.Ccr-10-1869 |
0.455 |
|
| 2011 |
Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 22: 515-23. PMID 20603440 DOI: 10.1093/Annonc/Mdq345 |
0.456 |
|
| 2011 |
Peeters D, van Dam P, Van den Eynden G, Benoy I, Van Laere SJ, van Dam PA, Huget P, Pauwels P, Peeters M, Vermeulen PB, Dirix LY. Detection of circulating tumor cells in patients with advanced breast cancer according to the immunohistochemical subtype. Journal of Clinical Oncology. 29: e21022-e21022. DOI: 10.1200/Jco.2011.29.15_Suppl.E21022 |
0.459 |
|
| 2011 |
Schooneveld Ev, Wouters M, Auwera IVd, Peeters D, Huget P, Dam PAv, Vermeulen PB, Laere SJV, Dirix LY. Detection of circulating miRNAs in serum from patients with breast cancer and their association with the presence of metastatic disease. Journal of Clinical Oncology. 29: 10506-10506. DOI: 10.1200/Jco.2011.29.15_Suppl.10506 |
0.383 |
|
| 2011 |
Eynden GGVd, Fiorentino M, Laere SSV, Peeters DS, Trinh XB, Dirix LY, Vermeulen PB. Abstract 5243: Gene expression analysis of CRC liver metastases with different growth patterns Cancer Research. 71: 5243-5243. DOI: 10.1158/1538-7445.Am2011-5243 |
0.308 |
|
| 2011 |
Marsan M, Limame R, François K, Bertucci F, Ueno N, Lardon F, Pauwels P, Dam PV, Vermeulen PB, Dirix LY, Laere SJV. Abstract 3427: A core invasiveness gene signature reveals reduced EMT in samples from patients with IBC, potentially regulated by decreased EGFR- and TGFb-signaling Cancer Research. 71: 3427-3427. DOI: 10.1158/1538-7445.Am2011-3427 |
0.459 |
|
| 2011 |
Laere SJV, Ueno N, Finetti P, Vermeulen PB, Lucci A, Birnbaum D, Robertson F, Iwamoto T, Dam PV, Woodward W, Viens P, Dirix LY, Reuben JR, Bertucci F. Abstract 328: An integrated analysis of three distinct IBC/non-IBC Affymetrix gene expression data sets to study the transcriptional heterogeneity both between IBC and non-IBC and within IBC Cancer Research. 71: 328-328. DOI: 10.1158/1538-7445.Am2011-328 |
0.349 |
|
| 2011 |
Trinh XB, Tjalma WA, Dirix LY, Vermeulen PB, Peeters D, Sas L, Gert VDEG, Laere SJV, Dam PAv. Abstract 3203: Oncogenic pathways analysis and survival outcome in advanced serous ovarian cancer Cancer Research. 71: 3203-3203. DOI: 10.1158/1538-7445.Am2011-3203 |
0.419 |
|
| 2011 |
Saura C, Bendell J, Jerusalem G, Graña-Suárez B, Su S, Ru Q, Buck SD, Devisme C, Bosch A, Urruticoechea A, Beck J, DiTomaso E, Rouyrre N, Sternberg D, Massacesi C, ... ... Dirix L, et al. PD09-03: Phase I/II Study of BKM120 in Combination with Trastuzumab in Patients with HER2 Overexpressing Metastatic Breast Cancer Resistant to Trastuzumab-Containing Therapy. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Pd09-03 |
0.401 |
|
| 2011 |
Laere SV, Ueno N, Finetti P, Vermeulen P, Lucci A, Birnbaum D, Robertson F, Dam Pv, Woodward W, Viens P, Dirix L, Reuben J, Iwamoto T, Cristofanilli M, Bertucci F. PD03-01: An Integrated Analysis of Three Distinct IBC/nIBC Affymetrix Gene Expression Data Sets Further Unveils the Molecular Biology of IBC. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Pd03-01 |
0.351 |
|
| 2011 |
van DP, Verheyden G, Trinh B, VanderMussele H, Wuyts H, Verkinderen L, Hauspy J, Vermeulen P, Dirix L. P5-23-06: Monitoring of Quality Indicators Should Lead to Quality Measures. A Dynamic Clinical Pathway for the Treatment of Patients with Early Breast Cancer Is a Tool for Better Cancer Care: Implementation and Prospective Analysis between 2002–2010. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P5-23-06 |
0.45 |
|
| 2011 |
Van dEG, Van LS, Smid M, Martens J, Foekens J, Vermeulen P, Dirix L. P5-14-14: The Presence of a Fibrotic Focus Adds Significant Prognostic Information to the Prognostic 76-Gene Relapse Score in Lymph Node Negative Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P5-14-14 |
0.402 |
|
| 2011 |
Van LS, Van GK, Joglekar M, Ueno N, Finetti P, Van DP, Viens P, Birnbaum D, Bertucci F, Vermeulen P, Dirix L. P5-01-01: Identification, Validation and Assessment of Transcriptional Relevance of a PDGFR-Activation Signature in (Inflammatory) Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P5-01-01 |
0.438 |
|
| 2011 |
Ryan P, Neven P, Blackwell K, Dirix L, Barrios C, Miller W, Fein L, Fenton D, Benner R, Meech S, Paccagnella L, Sleight B, Yee D, Goss P. P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-17-01 |
0.405 |
|
| 2011 |
Bianchi G, Kocsis J, Dirix L, Torigoe Y, Lalla D, Tong Y, Guardino A, Hurvitz S. P1-12-02: Patient-Reported Outcomes (PROs) from a Randomized Phase II Study (TDM4450g/BO21976) of Trastuzumab Emtansine (T-DM1) vs Trastuzumab Plus Docetaxel (HT) in Previously Untreated HER2−Positive Metastatic Breast Cancer (MBC). Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-12-02 |
0.361 |
|
| 2011 |
Water Wvd, Hille ETM, Hadji P, Markopoulos C, Seynaeve C, Hasenburg A, Dirix L, Rea D, Jones SE, Velde CJHvd. 5158 POSTER Specific Adverse Events and Outcome in Hormone Receptor Positive Breast Cancer Patients on Endocrine Therapy – a TEAM Study Analysis European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)71600-8 |
0.356 |
|
| 2011 |
Hurvitz S, Dirix L, Kocsis J, Gianni L, Lu J, Vinholes J, Song C, Tong B, Chu YW, Perez EA. 5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976) European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)71443-5 |
0.409 |
|
| 2011 |
Miles DW, Haas SLD, Romieu G, Chan A, Dirix L, Cortes J, Delmar PR, Scherer SJ. 1423 POSTER Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC) European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)70916-9 |
0.451 |
|
| 2011 |
Dirix L, Migden M, Oro A, Hauschild A, Lewis K, Mueller A, Yauch R, Reddy J, Sekulic A. A Pivotal Multicenter Trial Evaluating Efficacy and Safety of the Hedgehog Pathway Inhibitor (HPI) Vismodegib in Patients With Advanced Basal Cell Carcinoma (BCC) European Journal of Cancer. 47: 2. DOI: 10.1016/S0959-8049(11)70096-X |
0.351 |
|
| 2010 |
Dirix LY, Van Dam PA, Prove AM, Vermeulen PB. Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed? Therapeutic Advances in Medical Oncology. 2: 331-42. PMID 21789145 DOI: 10.1177/1758834010376301 |
0.367 |
|
| 2010 |
Van der Auwera I, Yu W, Suo L, Van Neste L, van Dam P, Van Marck EA, Pauwels P, Vermeulen PB, Dirix LY, Van Laere SJ. Array-based DNA methylation profiling for breast cancer subtype discrimination. Plos One. 5: e12616. PMID 20830311 DOI: 10.1371/Journal.Pone.0012616 |
0.434 |
|
| 2010 |
Van der Auwera I, Limame R, van Dam P, Vermeulen PB, Dirix LY, Van Laere SJ. Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. British Journal of Cancer. 103: 532-41. PMID 20664596 DOI: 10.1038/Sj.Bjc.6605787 |
0.341 |
|
| 2010 |
Van Laere S, Limame R, Van Marck EA, Vermeulen PB, Dirix LY. Is there a role for mammary stem cells in inflammatory breast carcinoma?: a review of evidence from cell line, animal model, and human tissue sample experiments. Cancer. 116: 2794-805. PMID 20503411 DOI: 10.1002/Cncr.25180 |
0.398 |
|
| 2010 |
Vermeulen PB, van Golen KL, Dirix LY. Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge. Cancer. 116: 2748-54. PMID 20503405 DOI: 10.1002/Cncr.25169 |
0.423 |
|
| 2010 |
Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3239-47. PMID 20498403 DOI: 10.1200/Jco.2008.21.6457 |
0.396 |
|
| 2010 |
van Nes JG, Seynaeve C, Jones S, Markopoulos C, Putter H, van de Velde CJ, Hasenburg A, Rea DW, Vannetzel JM, Dirix L, Hozumi Y, Kerin MJ, Kieback DG, Meershoek-Klein Kranenbarg WM, Hille ET, et al. Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries. The British Journal of Surgery. 97: 671-9. PMID 20393978 DOI: 10.1002/bjs.6962 |
0.318 |
|
| 2010 |
Van der Auwera I, Bovie C, Svensson C, Trinh XB, Limame R, van Dam P, van Laere SJ, van Marck EA, Dirix LY, Vermeulen PB. Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. Bmc Cancer. 10: 97. PMID 20226036 DOI: 10.1186/1471-2407-10-97 |
0.439 |
|
| 2010 |
Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, Awada A, Ranade A, Jiao S, Schwartz G, Abbas R, Powell C, Turnbull K, Vermette J, Zacharchuk C, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1301-7. PMID 20142587 DOI: 10.1200/Jco.2009.25.8707 |
0.44 |
|
| 2010 |
Van der Auwera I, Peeters D, Benoy IH, Elst HJ, Van Laere SJ, Prové A, Maes H, Huget P, van Dam P, Vermeulen PB, Dirix LY. Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. British Journal of Cancer. 102: 276-84. PMID 19953098 DOI: 10.1200/Jco.2009.27.15_Suppl.E22117 |
0.441 |
|
| 2010 |
Beuselinck B, Wildiers H, Wynendaele W, Dirix L, Kains J, Paridaens R. Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: A randomized phase-II study of the Belgian Society of Medical Oncology Critical Reviews in Oncology Hematology. 75: 70-77. PMID 19651523 DOI: 10.1016/J.Critrevonc.2009.07.001 |
0.459 |
|
| 2010 |
Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix LY, Rüttinger D, Schuler M, Reinhardt C, Awada A. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Annals of Oncology. 21: 275-282. PMID 19633042 DOI: 10.1093/Annonc/Mdp314 |
0.443 |
|
| 2010 |
Manikhas GM, Dirix L, Vermorken JB, Park K, Jain M, Thertulien R, Gonzalez M, Jiao J, Parekh TV, Staddon AP. A single-blind, placebo-controlled, sequential design study evaluating the potential effects of trabectedin on the QT intervals. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E13096 |
0.348 |
|
| 2010 |
Bartlett J, Brookes C, Velde Cvd, Stocken D, Campbell F, Hasenburg A, Kay C, Kiebeck D, Markopoulos C, Kranenbarg EM, Mallon E, Dirix L, Robson T, Seynaeve C, Rea D. Abstract S2-4: Final Results of a Prospectively Planned Biomarker Analysis: HER1-3 as Predictive Markers of Benefit from Early Treatment with Aromatase Inhibitors Versus Tamoxifen in the TEAM Pathology Sub-Study. Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-S2-4 |
0.438 |
|
| 2010 |
Seynaeve C, Hille E, Hasenburg A, Rea D, Markopoulos C, Hozumi Y, Putter H, Nortier H, Nes Jv, Dirix L, Velde Cvd. Abstract S2-3: The Impact of Body Mass Index (BMI) on the Efficacy of Adjuvant Endocrine Therapy in Postmenopausal Hormone Sensitive Breast Cancer (BC) Patients; Exploratory Analysis from the TEAM Study Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-S2-3 |
0.323 |
|
| 2010 |
Laere SV, Auwera IVd, Dam Pv, Vermeulen P, Dirix L. Abstract P6-04-07: Pathway Activation Probability Score Analysis Reveals Patterns of Pathway Deregulation in Inflammatory Breast Cancer Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P6-04-07 |
0.413 |
|
| 2010 |
Bartlett J, Gustavson M, Stocken D, Rimm D, Christiansen J, Velde Cvd, Hasenburg A, Kieback D, Putter H, Brookes C, Markopoulos C, Dirix L, Robson T, Seynaeve C, Dolled-Filhart M, et al. Abstract P4-08-02: A Comparison between AQUA Quantitative Fluorescent Immunohistochemistry and Conventional Immunohistochemistry for Hormone Receptors Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P4-08-02 |
0.396 |
|
| 2010 |
Cardoso F, Dirix L, Conte P, Semiglazov V, Placido Sd, Jaeger M, Mueller C, Eschenbach B, Klunker D, Lindhofer H, Cortes J. Abstract P3-14-21: Phase II Study of Single Agent Trifunctional Antibody Ertumaxomab (Anti-HER-2 & Anti-CD3) in HER-2 Low Expressing Hormone-Refractory Advanced Breast Cancer Patients (ABC) Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P3-14-21 |
0.419 |
|
| 2010 |
Staroslawska E, Dirix L, Luu T, Diéras V, Manso L, Xu B, Yang J, Abbas R, Strahs A, Van MV, Berkenblit A, Agrapart V, Powell C, Awada A. Abstract P3-14-05: Safety and Efficacy of Neratinib (HKI-272) Plus Vinorelbine in the Treatment of Patients with ErbB2+ Metastatic Breast Cancer Pretreated with Anti-HER2 Therapy Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P3-14-05 |
0.468 |
|
| 2010 |
Bartlett J, Bloom K, Goldstein N, Velde Cvd, Ross D, Seitz R, Beck R, Hasenburg A, Kieback D, Putter H, Markopoulos C, Dirix L, Robson T, Seynaeve C, Rea D. Abstract P3-10-33: Mammostrat® as an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in Postmenopausal Early Breast Cancer: Preliminary Data of the TEAM Pathology Study Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P3-10-33 |
0.424 |
|
| 2010 |
Bartlett J, Stocken D, Velde Cvd, Brookes C, Robson T, Hasenburg A, Hille E, Kiebeck D, Markopoulos C, Mallon E, Dirix L, Campbell F, Seynaeve C, Rea D. Abstract P3-10-04: An Integration of Biological and Pathological Marker Panel in the TEAM Pathology Sub-Study: The Impact of Different Parameters on Risk Estimation of Relapse at Both 2.75 and 5 Years Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P3-10-04 |
0.425 |
|
| 2010 |
Auwera IVd, Laere SV, Yu W, Dam Pv, Pauwels P, Marck EV, Vermeulen P, Dirix L. Abstract P3-04-01: Integrated Analysis of Epigenetic Signatures Associated with Inflammatory Breast Cancer Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P3-04-01 |
0.425 |
|
| 2010 |
Peeters D, Eynden GVd, Benoy I, Auwera IVd, Trinh X, Sas L, Laere SV, Dam Pv, Pauwels P, Peeters M, Vermeulen P, Dirix L. Abstract P3-02-10: Comparison of Circulating Tumour Cells in Peripheral and Central Venous Blood of Patients with Metastatic Breast Cancer: A Pilot Study Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P3-02-10 |
0.43 |
|
| 2010 |
Miles D, Haas Sd, Dirix L, Chan A, Pivot X, Tomczak P, Provencher L, Delmar P, Scherer S. Abstract P2-16-04: Plasma Biomarker Analyses in the AVADO Phase III Randomized Study of First-Line Bevacizumab + Docetaxel in Patients with Human Epidermal Growth Factor Receptor (HER) 2-Negative Metastatic Breast Cancer Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P2-16-04 |
0.45 |
|
| 2009 |
Limentani SA, Awada A, Dirix L, Beck J, Dieras V, Binlich F, Germa C, Agrapart V, Powell C, Hershman D. Safety and efficacy of neratinib (HKI-272) in combination with vinorelbine in patients with solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e14554. PMID 27963588 DOI: 10.1200/Jco.2009.27.15_Suppl.E14554 |
0.428 |
|
| 2009 |
Tabernero J, Dirix L, Schoffski P, Cervantes A, Capdevila J, Baselga J, van Beijsterveldt L, Winkler H, Kraljevic S, Zhuang SH. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2 antagonist JNJ-26854165 in patients with advanced refractory solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3514. PMID 27961305 DOI: 10.1200/Jco.2009.27.15_Suppl.3514 |
0.308 |
|
| 2009 |
Trinh XB, van Dam PA, Dirix LY, Vermeulen PB, Tjalma WA. The rationale for mTOR inhibition in epithelial ovarian cancer. Expert Opinion On Investigational Drugs. 18: 1885-91. PMID 19888868 DOI: 10.1517/13543780903321508 |
0.388 |
|
| 2009 |
Van der Auwera I, Bovie C, Svensson C, Limame R, Trinh XB, van Dam P, Van Laere SJ, Van Marck E, Vermeulen PB, Dirix LY. Quantitative assessment of DNA hypermethylation in the inflammatory and non-inflammatory breast cancer phenotypes. Cancer Biology & Therapy. 8: 2252-9. PMID 19829046 DOI: 10.4161/Cbt.8.23.10133 |
0.387 |
|
| 2009 |
Vermeulen PB, Van Laere SJ, Dirix LY. Inflammatory breast carcinoma as a model of accelerated self-metastatic expansion by intravascular growth. British Journal of Cancer. 101: 1028-9; author reply. PMID 19707200 DOI: 10.1038/Sj.Bjc.6605251 |
0.41 |
|
| 2009 |
Van der Auwera I, Elst HJ, Van Laere SJ, Maes H, Huget P, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY. The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. British Journal of Cancer. 100: 1277-86. PMID 19367284 DOI: 10.1038/Sj.Bjc.6605013 |
0.423 |
|
| 2009 |
Laere SJ, Vermeulen PB, Dirix LY. cDNA microarray analysis of inflammatory breast cancer signatures. Methods in Molecular Biology (Clifton, N.J.). 512: 71-98. PMID 19347274 DOI: 10.1007/978-1-60327-530-9_6 |
0.422 |
|
| 2009 |
Falandry C, Canney PA, Freyer G, Dirix LY. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 20: 615-20. PMID 19254941 DOI: 10.1093/annonc/mdn693 |
0.345 |
|
| 2009 |
Trinh XB, Tjalma WA, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, Helleman J, Berns EM, Dirix LY, van Dam PA. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. British Journal of Cancer. 100: 971-8. PMID 19240722 DOI: 10.1038/Sj.Bjc.6604921 |
0.334 |
|
| 2009 |
Wildiers H, Dirix L, Neven P, Prové A, Clement P, Squifflet P, Amant F, Skacel T, Paridaens R. Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment. 114: 103-112. PMID 18344024 DOI: 10.1007/S10549-008-9970-Z |
0.399 |
|
| 2009 |
Trinh X, Dam Pv, Tjalma W, Wojtasik A, Lybaert W, Rasschaert M, Rutten A, Prove A, Vermeulen P, Dirix L. An open-label phase II trial to assess to efficacy of sunitinib as an antieffusion agent in patients with malignant peritoneal and/or pleural effusions Journal of Clinical Oncology. 27. DOI: 10.1200/Jco.2009.27.15_Suppl.E14647 |
0.421 |
|
| 2009 |
Mauriac L, Cameron D, Dirix L, Blot E, Piccart M, Marreaud S, Tjan-Heijnen V, Cufer T, Bogaerts J, Basaran GA. Results of randomized phase II trial combining Iressa® (gefitinib) and arimidex in women with advanced breast cancer (ABC). EORTC protocol 10021. Cancer Research. 69: 6133. DOI: 10.1158/0008-5472.Sabcs-6133 |
0.45 |
|
| 2009 |
Beuselinck B, Wynendaele W, Dirix L, Wildiers H, Paridaens R, Kains J, Verhoeven D, Vandebroek J. Weekly paclitaxel versus weekly docetaxel in elderly and frail patients with metastatic breast carcinoma having failed previous anthracyclines: a randomised phase II study of the Belgian Society of Medical Oncology. Cancer Research. 69: 6115. DOI: 10.1158/0008-5472.Sabcs-6115 |
0.398 |
|
| 2009 |
Dam Pv, Weytjens R, DeMaeyer L, Dam Av, Alberty J, Verstraeten H, Huget P, Verkinderen L, Prove A, Vermeulen P, Dirix L. A prospective nonrandomize study comparing electron intraoperative boost radiotherapy versus postoperative interstitional brachytherapy in patients having breast conserving surgery and adjuvant external beam radiotherapy. Cancer Research. 69: 5140. DOI: 10.1158/0008-5472.Sabcs-5140 |
0.34 |
|
| 2009 |
Elst H, Auwera IVD, Vermeulen P, Prové A, Dam PV, Huget P, Dirix L. Isolation of circulating tumour cells in patients with metastatic breast cancer by filter technology. Cancer Research. 69: 5026. DOI: 10.1158/0008-5472.Sabcs-5026 |
0.333 |
|
| 2009 |
Auwera IVD, Elst H, Benoy I, Prové A, Wuyts H, Maes H, Dam PV, Huget P, Vermeulen P, Dirix L. Circulating tumour cell (CTC) detection: a direct comparison between the CellSearch system, the AdnaTest, CK19/MAM RT-PCR and unmethylated/methylated free DNA in patients with metastatic breast cancer. Cancer Research. 69: 5025. DOI: 10.1158/0008-5472.Sabcs-5025 |
0.426 |
|
| 2009 |
Auwera IVd, Elst H, Laere SV, Dam Pv, Marck EV, Vermeulen P, Dirix L. Association of serum tumor-related methylated DNA with circulating tumor cells in peripheral blood of breast cancer patients Cancer Research. 69: 5017. DOI: 10.1158/0008-5472.Sabcs-5017 |
0.404 |
|
| 2009 |
Dirix L, Romieu G, Provencher L, Grimes D, Viana LdS, Paterson A, Mauriac L, Kirsch A, Pernas S, Miles D. Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study. Cancer Research. 69: 4116. DOI: 10.1158/0008-5472.Sabcs-4116 |
0.349 |
|
| 2009 |
Burstein H, Sun Y, Tan A, Dirix L, Vermette J, Powell C, Zacharchuk C, Badwe R. Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer. Cancer Research. 69: 37. DOI: 10.1158/0008-5472.Sabcs-37 |
0.393 |
|
| 2009 |
Neskovic-Konstantinovic Z, Gomez H, Senkus-Konefka E, Dirix L, Jerusalem G, Murray E, Bottomley A, Rampion J, Duez N, Demonty G, Leo AD. A breast international group survey of young breast cancer patients' attitudes towards the risk of loss of fertility related to adjuvant therapies. EORTC protocol 10002 – BIG 3-98. Cancer Research. 69: 3106. DOI: 10.1158/0008-5472.Sabcs-3106 |
0.45 |
|
| 2009 |
Sweldens C, Huget P, Weytjens R, Prove A, Vermeulen P, Dam PV, Dirix L. Brain metastases (BM) in patients presenting with HER-2 amplified advanced breast cancer (ABC). Cancer Research. 69: 1060. DOI: 10.1158/0008-5472.Sabcs-1060 |
0.481 |
|
| 2009 |
Trinh B, Dam PV, Prové A, Maes H, Laere SV, Tjalma W, Huget P, Vermeulen P, Dirix L. Angiogenic escape and tumour progression in two patients with metastatic breast cancer receiving bevacizumab treatment. Cancer Research. 69: 1029. DOI: 10.1158/0008-5472.Sabcs-1029 |
0.454 |
|
| 2009 |
Auwera IVd, Laere SV, Limame R, Trinh X, Marck EV, Dam Pv, Dirix L, Vermeulen P. A microRNA Expression Profile Consisting of 12 microRNAs Is Associated with Inflammatory Breast Cancer. Cancer Research. 69: 6119-6119. DOI: 10.1158/0008-5472.Sabcs-09-6119 |
0.423 |
|
| 2009 |
Burstein H, Sun Y, Dirix L, Jiang Z, Paridaens R, Tan A, Awada A, Ranade A, Jiao S, Schwartz G, Powell C, Turnbull K, Vermette J, Zacharchuk C, Badwe R. Gastrointestinal and Cardiovascular Safety Profiles of Neratinib Monotherapy in Patients with Advanced ErbB2-Positive Breast Cancer. Cancer Research. 69: 5096-5096. DOI: 10.1158/0008-5472.Sabcs-09-5096 |
0.465 |
|
| 2009 |
Awada A, Dirix L, Beck J, Luu T, Dieras V, Llombart A, Manso L, Limentani S, Binlich F, Germa C, Abbas R, Agrapart V, Powell C, Hershman D. Safety and Efficacy of Neratinib (HKI-272) in Combination with Vinorelbine in ErbB2+ Metastatic Breast Cancer. Cancer Research. 69: 5095-5095. DOI: 10.1158/0008-5472.Sabcs-09-5095 |
0.454 |
|
| 2009 |
Harbeck N, Schmidt M, Harter P, Possinger K, Jonat W, Lück H, Beckmann M, Fasching P, Schütte J, Solca F, Uttenreuther-Fischer M, Taton M, Lahogue A, Awada A, Grève JD, ... ... Dirix L, et al. BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor for the Treatment of Patients with HER2-Negative Metastatic Breast Cancer after Failure of No More Than Two Prior Chemotherapies. Cancer Research. 69: 5062-5062. DOI: 10.1158/0008-5472.Sabcs-09-5062 |
0.484 |
|
| 2009 |
Miles D, Chan A, Romieu G, Dirix L, Cortés J, Pivot X, Tomczak P, Juozaityte E, Harbeck N, Steger G. Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC). Cancer Research. 69: 41-41. DOI: 10.1158/0008-5472.Sabcs-09-41 |
0.369 |
|
| 2009 |
Laere SV, Auwera IVd, Limame R, Trinh X, Marck EV, Dam Pv, Vermeulen P, Dirix L. A microRNA Expression Profile Consisting of 15 microRNAs, Including miR205, Is Associated with Poor Prognosis in Breast Cancer. Cancer Research. 69: 4062-4062. DOI: 10.1158/0008-5472.Sabcs-09-4062 |
0.386 |
|
| 2009 |
Jansen M, Ruigrok-Ritstier K, Kok M, Reijm E, Gelder MM, Look M, Staveren Iv, Sieuwerts A, Weerd Vd, Smid M, Martens J, Simon I, Tian S, Glas A, Wuyts H, ... ... Dirix L, et al. Integrated Genomic Profiling of Endocrine Therapy Response in Advanced Breast Cancer. Cancer Research. 69: 3029-3029. DOI: 10.1158/0008-5472.Sabcs-09-3029 |
0.417 |
|
| 2009 |
Peeters D, Benoy I, Eynden GVd, Auwera IVd, Laere SV, Trinh X, Limame R, Huget P, Dam Pv, Vermeulen P, Dirix L. Prognostic Significance of Real-Time RT-PCR Detection of Disseminated Tumour Cells in Bone Marrow and Circulating Tumour Cells in Patients with Breast Cancer. Cancer Research. 69: 3019-3019. DOI: 10.1158/0008-5472.Sabcs-09-3019 |
0.429 |
|
| 2009 |
Auwera IVd, Renard I, Eynden GVd, Limame R, Trinh X, Dam Pv, Marck EV, Laere SV, Vermeulen P, Dirix L. Gene Promoter Hypermethylation in Tumors and Matched Affected Lymph Nodes of Breast Cancer Patients. Cancer Research. 69: 1149-1149. DOI: 10.1158/0008-5472.Sabcs-09-1149 |
0.407 |
|
| 2009 |
Nes JGHv, Seynaeve C, Jones S, Hasenburg A, Rea DW, Vannetzel JM, Dirix L, Markopoulos C, Kranenbarg WMM, Velde CJHvd. 5139 Patterns of care in postmenopausal early breast cancer patients participating in the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study: variations in locoregional therapy between different countries Ejc Supplements. 7: 301. DOI: 10.1016/S1359-6349(09)71031-6 |
0.425 |
|
| 2009 |
Cardoso F, Canon JL, Amadori D, Dirix L, Villa E, Aldrighetti D, Machiels J, Verkh L, Kern K, Giorgetti C. 5075 Sunitinib plus docetaxel and trastuzumab as first-line therapy for HER2+ advanced breast cancer Ejc Supplements. 7: 283. DOI: 10.1016/S1359-6349(09)70967-X |
0.447 |
|
| 2008 |
Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, Tomczak P, Taran T, Harbeck N, Steger GG. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: LBA1011. PMID 27951290 DOI: 10.1200/Jco.2008.26.15_Suppl.Lba1011 |
0.423 |
|
| 2008 |
Van Laere S, Beissbarth T, Van der Auwera I, Van den Eynden G, Trinh XB, Elst H, Van Hummelen P, van Dam P, Van Marck E, Vermeulen P, Dirix L. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7452-60. PMID 19010862 DOI: 10.1158/1078-0432.Ccr-08-1077 |
0.488 |
|
| 2008 |
Van der Auwera I, Van Laere SJ, Van den Bosch SM, Van den Eynden GG, Trinh BX, van Dam PA, Colpaert CG, van Engeland M, Van Marck EA, Vermeulen PB, Dirix LY. Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype. British Journal of Cancer. 99: 1735-42. PMID 18841156 DOI: 10.1038/Sj.Bjc.6604705 |
0.374 |
|
| 2008 |
Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P. Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group Journal of Clinical Oncology. 26: 4883-4890. PMID 18794551 DOI: 10.1200/Jco.2007.14.4659 |
0.497 |
|
| 2008 |
Van den Eynden GG, Smid M, Van Laere SJ, Colpaert CG, Van der Auwera I, Bich TX, van Dam P, den Bakker MA, Dirix LY, Van Marck EA, Vermeulen PB, Foekens JA. Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2944-52. PMID 18483361 DOI: 10.1158/1078-0432.Ccr-07-4397 |
0.412 |
|
| 2008 |
Awada A, Albanell J, Canney PA, Dirix LY, Gil T, Cardoso F, Gascon P, Piccart MJ, Baselga J. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. British Journal of Cancer. 98: 1500-1507. PMID 18454159 DOI: 10.1038/Sj.Bjc.6604347 |
0.446 |
|
| 2008 |
Dirix LY, Ignacio J, Nag S, Bapsy P, Gomez H, Raghunadharao D, Paridaens R, Jones S, Falcon S, Carpentieri M, Abbattista A, Lobelle JP. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1253-9. PMID 18323548 DOI: 10.1200/Jco.2007.13.3744 |
0.492 |
|
| 2008 |
Awada A, Cardoso F, Fontaine C, Dirix L, Grève JD, Sotiriou C, Steinseifer J, Wouters C, Tanaka C, Zoellner U, Tang P, Piccart M. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. European Journal of Cancer. 44: 84-91. PMID 18039566 DOI: 10.1016/J.Ejca.2007.10.003 |
0.449 |
|
| 2008 |
Neven P, Paridaens R, Pelgrims G, Martens M, Bols A, Goeminne JC, Vindevoghel A, Demol J, Stragier B, Greve JD, Fontaine C, Weyngaert DVD, Becquart D, Borms M, Cocquyt V, ... ... Dirix L, et al. Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study. Breast Cancer Research and Treatment. 109: 59-65. PMID 17592772 DOI: 10.1007/S10549-007-9628-2 |
0.454 |
|
| 2008 |
Trinh X, Tjalma WA, Dirix LY, Vermeulen PB, Eynden GGVd, Laere SJV, Auwera IVD, Dam PAv. Anti-VEGF treatments in epithelial ovarian cancer: Is it only anti-angiogenesis? Journal of Clinical Oncology. 26: 14548-14548. DOI: 10.1200/Jco.2008.26.15_Suppl.14548 |
0.419 |
|
| 2008 |
Laere SJV, Eynden GGVd, Auwera IVd, Trinh XB, Dam PAv, Marck EAV, Vermeulen PB, Dirix LY. Inflammatory breast carcinoma signature and relapse-free survival in patients with noninflammatory breast cancer Journal of Clinical Oncology. 26: 11048-11048. DOI: 10.1200/Jco.2008.26.15_Suppl.11048 |
0.451 |
|
| 2008 |
Laere SV, Auwera IVd, Eynden GVd, Trinh XB, Dam Pv, Marck EV, Vermeulen P, Dirix L. An inflammatory breast carcinoma signature is associated with reduced relapse free survival in patients with non-inflammatory breast cancer Ejc Supplements. 6: 105-105. DOI: 10.1016/S1359-6349(08)71577-5 |
0.451 |
|
| 2008 |
Beuselinck B, Wildiers H, Wynendaele W, Dirix L, Kains J, Vandebroek J, Verhoeven D, Paridaens R. Toxiticy data of a randomised Phase II study comparing weekly paclitaxel versus weekly docetaxel in elderly and frail patients with metastatic breast cancer Critical Reviews in Oncology Hematology. 68. DOI: 10.1016/S1040-8428(08)70046-5 |
0.475 |
|
| 2008 |
Brussel SV, Deckers F, Laere SV, Sprangers A, Huget P, Dirix L, Weytjens R. IMRT for Rectal Cancer Patients Based on Diffusion Weighted MRI (DWMRI) International Journal of Radiation Oncology Biology Physics. 72. DOI: 10.1016/J.Ijrobp.2008.06.646 |
0.329 |
|
| 2007 |
Paridaens R, Dirix L, Dumez H, Prové A, Wildiers H, Alvarez A, Oliveira CT, Latz J, Simms L, Melemed A. Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer. Clinical Breast Cancer. 7: 861-6. PMID 18269776 DOI: 10.3816/Cbc.2007.N.051 |
0.444 |
|
| 2007 |
van Dam PA, van Dam PJ, Verkinderen L, Vermeulen P, Deckers F, Dirix LY. Robotic-assisted laparoscopic cytoreductive surgery for lobular carcinoma of the breast metastatic to the ovaries. Journal of Minimally Invasive Gynecology. 14: 746-9. PMID 17980337 DOI: 10.1016/J.Jmig.2007.06.004 |
0.372 |
|
| 2007 |
Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crino L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Annals of Oncology. 19: 420-432. PMID 17906299 DOI: 10.1093/Annonc/Mdm442 |
0.422 |
|
| 2007 |
Van den Eynden GG, Vandenberghe MK, van Dam PJ, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA. Increased sentinel lymph node lymphangiogenesis is associated with nonsentinel axillary lymph node involvement in breast cancer patients with a positive sentinel node. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5391-7. PMID 17875768 DOI: 10.1158/1078-0432.Ccr-07-1230 |
0.383 |
|
| 2007 |
Van Laere S, Van der Auwera I, Van den Eynden G, Van Hummelen P, van Dam P, Van Marck E, Vermeulen PB, Dirix L. Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis. British Journal of Cancer. 97: 1165-74. PMID 17848951 DOI: 10.1038/Sj.Bjc.6603967 |
0.358 |
|
| 2007 |
Van den Eynden GG, Van der Auwera I, Colpaert CG, Dirix LY, Van Marck EA, Vermeulen PB. Letter to the editor: Lymphangiogenesis in primary breast cancer. Cancer Letters. 256: 279-81; author reply. PMID 17714860 DOI: 10.1016/J.Canlet.2007.07.005 |
0.455 |
|
| 2007 |
Van Laere SJ, Van der Auwera I, Van den Eynden GG, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. British Journal of Cancer. 97: 659-69. PMID 17700572 DOI: 10.1038/Sj.Bjc.6603906 |
0.342 |
|
| 2007 |
Van den Eynden GG, Van der Auwera I, Van Laere SJ, Trinh XB, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA. Comparison of molecular determinants of angiogenesis and lymphangiogenesis in lymph node metastases and in primary tumours of patients with breast cancer. The Journal of Pathology. 213: 56-64. PMID 17674348 DOI: 10.1002/Path.2211 |
0.402 |
|
| 2007 |
Van den Eynden GG, Colpaert CG, Couvelard A, Pezzella F, Dirix LY, Vermeulen PB, Van Marck EA, Hasebe T. A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation. Histopathology. 51: 440-51. PMID 17593207 DOI: 10.1111/j.1365-2559.2007.02761.x |
0.361 |
|
| 2007 |
Van den Eynden GG, Van Laere SJ, Van der Auwera I, Gilles L, Burn JL, Colpaert C, van Dam P, Van Marck EA, Dirix LY, Vermeulen PB. Differential expression of hypoxia and (lymph)angiogenesis-related genes at different metastatic sites in breast cancer. Clinical & Experimental Metastasis. 24: 13-23. PMID 17295094 DOI: 10.1007/S10585-006-9049-3 |
0.45 |
|
| 2007 |
Giuliani R, Durbecq V, Leo AD, Paesmans M, Larsimont D, Leroy J, Borms M, Vindevoghel A, Jerusalem G, D’Hondt V, Dirix L, Canon J, Richard V, Cocquyt V, Majois F, et al. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC) European Journal of Cancer. 43: 725-735. PMID 17251007 DOI: 10.1016/J.Ejca.2006.11.019 |
0.345 |
|
| 2007 |
Awada AH, Schmidt M, Scheulen ME, Obrist P, Marschner N, Dirix L, Dittrich C, Reinhardt C, Schuler M. Final results from an open-label, randomised, phase II study of adecatumumab (MT201), a fully human anti-EpCAM antibody, in patients with metastatic breast cancer Journal of Clinical Oncology. 25: 3588-3588. DOI: 10.1200/Jco.2007.25.18_Suppl.3588 |
0.488 |
|
| 2007 |
Laere SJV, Auwera IVd, Eynden GGVd, Trinh X, Hummelen PV, Dam Pv, Marck EAV, Vermeulen PB, Dirix LY. Confirmation of the distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene expression analysis Journal of Clinical Oncology. 25: 21055-21055. DOI: 10.1200/Jco.2007.25.18_Suppl.21055 |
0.451 |
|
| 2007 |
Trinh X, Tjalma WA, Dirix LY, Vermeulen PB, Van Den Eynden GG, Van Laere SJ, Van Der Auwera I, van Dam PA. The correlation of the AKT/mTOR/p70S6K1 pathway and VEGF in human epithelial ovarian cancer Journal of Clinical Oncology. 25: 16081-16081. DOI: 10.1200/Jco.2007.25.18_Suppl.16081 |
0.399 |
|
| 2007 |
Dirix LY, Prové A, Sweldens C, Dam PV, Vermeulen P, Benoy I. Phase II study of docetaxel, carboplatin and trastuzumab (THC) in patients with locally advanced breast cancer Journal of Clinical Oncology. 25: 1062-1062. DOI: 10.1200/Jco.2007.25.18_Suppl.1062 |
0.46 |
|
| 2007 |
Verheyden G, Mussele Hvd, Prove AM, Verkinderen L, Schepper AD, Vermeulen PB, Buelens G, Pooter CD, Dirix LY, Dam Pv. 8015 ORAL Stepwise implementation of an evidence-based specialist breast care nurse model in a Belgian breast cancer clinic: Impact on patient's satisfaction, a prospective study Ejc Supplements. 5: 416. DOI: 10.1016/S1359-6349(07)71519-7 |
0.412 |
|
| 2007 |
Trinh XB, Tjalma WAA, Dirix LY, Vemeulen PB, Eynden GGvD, Laere SJv, Auwera IvD, Dam PAv. 5007 ORAL Correlation of the AKT/mTOR/p70S6K1 pathway and phosphorylated vascular endothelial growth factor receptor 2 in human epithelial ovarian cancer Ejc Supplements. 5: 313-313. DOI: 10.1016/S1359-6349(07)71179-5 |
0.312 |
|
| 2007 |
Wildiers H, Dirix L, Neven P, Prové A, Clement P, Amant F, Paridaens R. 2083 POSTER Adjuvant delivery of a dose-dense, sequential FEC-docetaxel regimen to patients with high-risk breast cancer is feasible – results of a randomized, open-label Phase II study Ejc Supplements. 5: 208. DOI: 10.1016/S1359-6349(07)70845-5 |
0.441 |
|
| 2007 |
Eynden GGvd, Auwera Ivd, Laere SJv, Colpaert CG, Dam Pv, Dirix LY, Vermeulen PB, Marck EAv. 313 POSTER Comparison of molecular determinants of angiogenesis and lymphangiogenesis in lymph node metastases and in primary tumours of patients with breast cancer Ejc Supplements. 5: 60-61. DOI: 10.1016/S1359-6349(07)70331-2 |
0.429 |
|
| 2007 |
Karnon J, Berli`ere M, Depypere H, Dirix L, Jerusalem G, Neven P, Paridaens R, Lecomte P. P181 Cost-effectiveness analysis of letrozole vs. tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer: the Belgian perspective The Breast. 16. DOI: 10.1016/S0960-9776(07)70241-2 |
0.398 |
|
| 2006 |
Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, Harris AL, Dirix LY, Vermeulen PB. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. British Journal of Cancer. 95: 1611-25. PMID 17117184 DOI: 10.1038/Sj.Bjc.6603445 |
0.347 |
|
| 2006 |
Van den Eynden GG, Van der Auwera I, Van Laere SJ, Huygelen V, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA. Induction of lymphangiogenesis in and around axillary lymph node metastases of patients with breast cancer. British Journal of Cancer. 95: 1362-6. PMID 17088912 DOI: 10.1038/Sj.Bjc.6603443 |
0.447 |
|
| 2006 |
Vermeulen PB, Van Laere SL, Dirix LY. How to measure and report the estrogen (and progesterone) receptor in breast cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 16: 529-32. PMID 17010066 DOI: 10.1111/J.1525-1438.2006.00689.X |
0.418 |
|
| 2006 |
Dirix LY, Van Dam P, Prové A, Vermeulen PB. Inflammatory breast cancer: current understanding. Current Opinion in Oncology. 18: 563-71. PMID 16988576 DOI: 10.1097/01.Cco.0000245307.29026.0A |
0.462 |
|
| 2006 |
Benoy IH, Elst H, Van Dam P, Scharpé S, Van Marck E, Vermeulen PB, Dirix LY. Detection of circulating tumour cells in blood by quantitative real-time RT-PCR: effect of pre-analytical time. Clinical Chemistry and Laboratory Medicine. 44: 1082-7. PMID 16958599 DOI: 10.1515/Cclm.2006.210 |
0.338 |
|
| 2006 |
Van der Auwera I, Colpaert C, Van Marck E, Vermeulen P, Dirix L. Lymphangiogenesis in breast cancer. The American Journal of Surgical Pathology. 30: 1055-6; author reply. PMID 16861982 DOI: 10.1097/00000478-200608000-00021 |
0.452 |
|
| 2006 |
Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpé S, Van Marck E, Vermeulen PB, Dirix LY. Prognostic significance of disseminated tumor cells as detected by quantitative real-time reverse-transcriptase polymerase chain reaction in patients with breast cancer. Clinical Breast Cancer. 7: 146-52. PMID 16800974 DOI: 10.3816/Cbc.2006.N.024 |
0.425 |
|
| 2006 |
Van Laere SJ, Van der Auwera I, Van den Eynden GG, Elst HJ, Weyler J, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3249-56. PMID 16740744 DOI: 10.1158/1078-0432.Ccr-05-2800 |
0.428 |
|
| 2006 |
Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. British Journal of Cancer. 94: 1643-9. PMID 16670715 DOI: 10.1038/Sj.Bjc.6603152 |
0.384 |
|
| 2006 |
Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, Batter V, Ngalula-Kabanga E, Dittrich C, Piccart M. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993) European Journal of Cancer. 42: 882-887. PMID 16520033 DOI: 10.1016/J.Ejca.2005.12.011 |
0.447 |
|
| 2006 |
Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpé S, Van Marck E, Vermeulen PB, Dirix LY. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. British Journal of Cancer. 94: 672-80. PMID 16495933 DOI: 10.1038/Sj.Bjc.6602985 |
0.407 |
|
| 2006 |
Van Laere SJ, Van den Eynden GG, Van der Auwera I, Vandenberghe M, van Dam P, Van Marck EA, van Golen KL, Vermeulen PB, Dirix LY. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Research and Treatment. 95: 243-55. PMID 16261404 DOI: 10.1007/S10549-005-9015-9 |
0.42 |
|
| 2006 |
Van den Eynden GG, Van Laere SJ, Van der Auwera I, Merajver SD, Van Marck EA, van Dam P, Vermeulen PB, Dirix LY, van Golen KL. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Research and Treatment. 95: 219-28. PMID 16244790 DOI: 10.1007/S10549-005-9002-1 |
0.463 |
|
| 2006 |
Dirix L, Van Dam P, Vermeulen P. Genomics and circulating tumor cells: promising tools for choosing and monitoring adjuvant therapy in patients with early breast cancer? Current Opinion in Oncology. 17: 551-8. PMID 16224232 DOI: 10.1097/01.Cco.0000183669.61767.81 |
0.466 |
|
| 2006 |
Cardoso F, Azambuja, Bernard C, Dirix L, Becker DD, Bartholomeus S, Hondt VD, Velde Hvd, Piccart M, Awada A. A phase I, open label, dose-escalating study of the proteasome inhibitor PS-341 (VELCADE¢) in combination with two schedules of trastuzumab, in patients with advanced breast cancer (ABC) that overexpresses HER-2* Ejc Supplements. 4: 173. DOI: 10.1016/S1359-6349(06)80449-0 |
0.46 |
|
| 2006 |
Dirix L, Benoy, Prové A, Elst H, Vandebroeck J, Wuyts H, Philips M, Deleu I, Dam PV, Vermeulen P. Phase II study of Docetaxel, Carboplatin, and Trastuzumab (THC) as first-line treatment in patients with HER-2 amplified advanced breast cancer. Changes in circulating tumor cells (CTC), total plasma DNA and circulating HER-2 ECD Ejc Supplements. 4: 161. DOI: 10.1016/S1359-6349(06)80408-8 |
0.445 |
|
| 2006 |
Laere SV, Auwera Vd, Eynden GVd, Huygelen V, Elst H, Dam Pv, Marck EV, Vermeulen P, Dirix L. Inflammatory breast cancer: at the cross-roads of NFkB and estrogen receptor signalling pathways? Ejc Supplements. 4: 136-137. DOI: 10.1016/S1359-6349(06)80325-3 |
0.397 |
|
| 2006 |
Auwera IVd, Elst, Huygelen V, Laere SV, Eynden GVd, Dam Pv, Marck EV, Vermeulen P, Dirix L. Real-time RT-PCR of CD146 and VE-cadherin mRNA to detect circulating endothelial cells in peripheral blood of patients with breast cancer Ejc Supplements. 4: 126. DOI: 10.1016/S1359-6349(06)80292-2 |
0.393 |
|
| 2006 |
Laere SV, Eynden Vd, Auwera IVd, Huygelen V, Elst H, Colpaert C, Dam Pv, Marck EV, Vermeulen P, Dirix L. Identification of cell-of-origin subtypes and a wound healing response signature in inflammatory breast cancer Ejc Supplements. 4: 125-126. DOI: 10.1016/S1359-6349(06)80289-2 |
0.417 |
|
| 2006 |
Eynden GVd, Auwera Vd, Laere SV, Colpaert C, Dam Pv, Marck EV, Vermeulen P, Dirix L. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective study in 95 patients Ejc Supplements. 4: 122. DOI: 10.1016/S1359-6349(06)80275-2 |
0.457 |
|
| 2005 |
Morikawa A, Williams TY, Dirix L, Colpaert C, Goodman M, Lyles RH, Zhong D, Zhou W. Allelic imbalances of chromosomes 8p and 18q and their roles in distant relapse of early stage, node-negative breast cancer. Breast Cancer Research : Bcr. 7: R1051-7. PMID 16457686 DOI: 10.1186/Bcr1349 |
0.448 |
|
| 2005 |
Van der Auwera I, Van den Eynden GG, Colpaert CG, Van Laere SJ, van Dam P, Van Marck EA, Dirix LY, Vermeulen PB. Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7637-42. PMID 16278382 DOI: 10.1158/1078-0432.Ccr-05-1142 |
0.448 |
|
| 2005 |
Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, Turley H, Harris AL, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA. Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer. British Journal of Cancer. 93: 1128-36. PMID 16251878 DOI: 10.1038/Sj.Bjc.6602828 |
0.383 |
|
| 2005 |
Van Laere S, Van der Auwera I, Van den Eynden GG, Fox SB, Bianchi F, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Research and Treatment. 93: 237-46. PMID 16172796 DOI: 10.1007/S10549-005-5157-Z |
0.453 |
|
| 2005 |
Van Cutsem E, Dirix L, Van Laethem JL, Van Belle S, Borner M, Gonzalez Baron M, Roth A, Morant R, Joosens E, Gruia G, Sibaud D, Bleiberg H. Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: Results from a multinational, randomised phase II study British Journal of Cancer. 92: 1055-1062. PMID 15756271 DOI: 10.1038/Sj.Bjc.6602462 |
0.338 |
|
| 2005 |
Benoy IH, Salgado R, Elst H, Van Dam P, Weyler J, Van Marck E, Scharpé S, Vermeulen PB, Dirix LY. Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer. Breast Cancer Research : Bcr. 7: R210-9. PMID 15743502 DOI: 10.1186/Bcr980 |
0.35 |
|
| 2005 |
Benoy I, Elst H, dan der Auwera I, van Laere S, dan den Eynden G, van Dam P, van Marck E, Vermeulen P, Dirix L. Detection of disseminated epithelial cells in patients with breast cancer: comparison of blood and bone marrow for CK19 en MAM mRNA expression Journal of Clinical Oncology. 23: 9539-9539. DOI: 10.1200/Jco.2005.23.16_Suppl.9539 |
0.41 |
|
| 2004 |
Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, Fox SB, Turley H, Harris AL, Van Marck EA, Vermeulen PB, Dirix LY. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 7965-71. PMID 15585631 DOI: 10.1158/1078-0432.Ccr-04-0063 |
0.465 |
|
| 2004 |
Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpé S, Vermeulen PB, Dirix LY. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 7157-62. PMID 15534087 DOI: 10.1158/1078-0432.Ccr-04-0812 |
0.462 |
|
| 2004 |
Benoy IH, Elst H, Van der Auwera I, Van Laere S, van Dam P, Van Marck E, Scharpé S, Vermeulen PB, Dirix LY. Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer. British Journal of Cancer. 91: 1813-20. PMID 15505629 DOI: 10.1038/Sj.Bjc.6602189 |
0.379 |
|
| 2004 |
Salgado R, Benoy I, Vermeulen P, Dam Pv, Marck EV, Dirix L. Circulating basic fibroblast growth factor is partly derived from the tumour in patients with colon, cervical and ovarian cancer. Angiogenesis. 7: 29-32. PMID 15302993 DOI: 10.1023/B:Agen.0000037331.14489.0B |
0.347 |
|
| 2004 |
Stessels F, Van den Eynden G, Van der Auwera I, Salgado R, Van den Heuvel E, Harris AL, Jackson DG, Colpaert CG, van Marck EA, Dirix LY, Vermeulen PB. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. British Journal of Cancer. 90: 1429-36. PMID 15054467 DOI: 10.1038/Sj.Bjc.6601727 |
0.313 |
|
| 2004 |
Van den Eynden GG, Van der Auwera I, Van Laere S, Colpaert CG, van Dam P, Merajver S, Kleer CG, Harris AL, Van Marck EA, Dirix LY, Vermeulen PB. Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Research and Treatment. 85: 13-22. PMID 15039594 DOI: 10.1023/B:Brea.0000021028.33926.A8 |
0.44 |
|
| 2004 |
Atalay G, Dirix LY, Biganzoli L, Beex LVAM, Nooij MA, Cameron D, Lohrisch C, Cufer T, Lobelle JP, Mattiaci MR, Piccart M, Paridaens R. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Annals of Oncology. 15: 211-217. PMID 14760111 DOI: 10.1093/Annonc/Mdh064 |
0.42 |
|
| 2004 |
Dam Pv, Sonnemans H, Dam Pv, Verkinderen L, Dirix LY. Sentinel node detection in patients with vaginal carcinoma Gynecologic Oncology. 92: 89-92. PMID 14751143 DOI: 10.1016/J.Ygyno.2003.08.006 |
0.331 |
|
| 2004 |
Paridaens R, Therasse P, Dirix L, Beex L, Piccart M, Cameron D, Cufer T, Roozendaal K, Nooij M, Mattiacci M-. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group Journal of Clinical Oncology. 22: 515-515. DOI: 10.1200/Jco.2004.22.90140.515 |
0.379 |
|
| 2004 |
Paridaens R, Therasse P, Dirix L, Beex L, Piccart MJ, Cameron D, Cufer T, Roozendael K, Nooy M, Mattiacci MR. First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) — EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group Ejc Supplements. 2: 126. DOI: 10.1016/S1359-6349(04)90844-0 |
0.382 |
|
| 2003 |
Colpaert CG, Vermeulen PB, Fox SB, Harris AL, Dirix LY, Van Marck EA. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Research and Treatment. 81: 137-47. PMID 14572156 DOI: 10.1023/A:1025702330207 |
0.358 |
|
| 2003 |
Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Duchateau L, Hamilton A, Lobelle JP, Piccart M. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer Annals of Oncology. 14: 1391-1398. PMID 12954578 DOI: 10.1093/Annonc/Mdg362 |
0.404 |
|
| 2003 |
Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. International Journal of Cancer. 103: 642-6. PMID 12494472 DOI: 10.1002/ijc.10833 |
0.32 |
|
| 2003 |
Salgado R, Benoy I, van Marck E, Vermeulen P, Dirix L. The importance of the VEGF-load in platelets in cancer patients. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 13: 1689-90. PMID 12377663 DOI: 10.1093/Annonc/Mdf320 |
0.312 |
|
| 2003 |
Paridaens R, Dirix L, Mellaerts N, Downie L, Munoz M, Gillard P, Dumez H. 290. Phase I Study of Pemetrexed (ALIMTA) and Epirubicin in Patients with Locally Advanced or Metastatic Breast Cancer Breast Cancer Research and Treatment. 79: 280-280. DOI: 10.1023/A:1023983327622 |
0.494 |
|
| 2002 |
Van den Eynden GG, Colpaert CG, Vermeulen PB, Weyler JJ, Goovaerts G, van Dam P, Van Marck EA, Dirix LY. Comparative analysis of the biochemical and immunohistochemical determination of hormone receptors in invasive breast carcinoma influence of the tumor-stroma ratio. Pathology, Research and Practice. 198: 517-24. PMID 12389994 DOI: 10.1078/0344-0338-00295 |
0.381 |
|
| 2002 |
Vermeulen PB, Fox SB, Dirix LY, Colpaert C, Van Marck EA. Heterogeneity of vascularisation in invasive breast carcinoma. European Journal of Cancer (Oxford, England : 1990). 38: 1951-2. PMID 12204679 DOI: 10.1016/S0959-8049(02)00156-9 |
0.373 |
|
| 2002 |
Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clinical Breast Cancer. 2: 311-5. PMID 11899364 DOI: 10.3816/Cbc.2002.N.008 |
0.386 |
|
| 2002 |
Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, Van Dam P, Prové A, Lemmens J, Vermeulen P. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer British Journal of Cancer. 86: 389-395. PMID 11875705 DOI: 10.1038/sj.bjc.6600069 |
0.316 |
|
| 2001 |
Salgado R, Benoy I, Bogers J, Weytjens R, Vermeulen P, Dirix L, Marck EV. Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study. Angiogenesis. 4: 37-43. PMID 11824377 DOI: 10.1023/A:1016611230747 |
0.314 |
|
| 2001 |
Colpaert C, Vermeulen P, Van Marck E, Dirix L. The presence of a fibrotic focus is an independent predictor of early metastasis in lymph node-negative breast cancer patients. The American Journal of Surgical Pathology. 25: 1557-8. PMID 11717549 DOI: 10.1097/00000478-200112000-00016 |
0.303 |
|
| 2001 |
Colpaert C, Vermeulen P, Van Beest P, Goovaerts G, Weyler J, Van Dam P, Dirix L, Van Marck E. Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients Histopathology. 39: 416-425. PMID 11683944 DOI: 10.1046/J.1365-2559.2001.01238.X |
0.448 |
|
| 2001 |
Schellens JH, Dombernowsky P, Cassidy J, Epelbaum R, Dirix L, Cox EH, Wanders J, Calabresi F, Paridaens R, Monfardini S, Wolff J, Loos WJ, Verweij J, Pavlidis N, Hanauske AR. Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9 Anti-Cancer Drugs. 12: 583-590. PMID 11487714 DOI: 10.1097/00001813-200108000-00004 |
0.301 |
|
| 2001 |
Colpaert C, Vermeulen P, Jeuris W, van Beest P, Goovaerts G, Weyler J, Van Dam P, Dirix L, Van Marck E. Early distant relapse in "node-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. The Journal of Pathology. 193: 442-9. PMID 11276002 DOI: 10.1002/Path.829 |
0.428 |
|
| 2001 |
Cutsem EV, Laethem JV, Dirix L, Humblet Y, Eygen KV, Demol J, Bleiberg H, Verslype C, Vermaut R, Daems K. Phase II study of raltitrexed in combination with oxaliplatin as second line treatment in refractory advanced colorectal cancer European Journal of Cancer. 37. DOI: 10.1016/S0959-8049(01)81500-8 |
0.35 |
|
| 2001 |
Junius S, Benoy I, Salgado R, Weytjens R, Dam PV, Huget P, Lemmens J, Dirix L. Serum IL-6 (sIL-6) predicts overall survival in patients with metastatic breast cancer (MBC) European Journal of Cancer. 37. DOI: 10.1016/S0959-8049(01)81209-0 |
0.428 |
|
| 2000 |
Paridaens R, Dirix L, Beex L, Nooij M, Cufer T, Lohrisch C, Biganzoli L, Hoorebeeck IV, Duchateau L, Lobelle J, Piccart M. Promising Results with Exemestane in the First-Line Treatment of Metastatic Breast Cancer: A Randomized Phase II EORTC Trial with a Tamoxifen Control Clinical Breast Cancer. 1. PMID 11970745 DOI: 10.3816/Cbc.2000.S.004 |
0.437 |
|
| 2000 |
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, et al. Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study. Clinical Breast Cancer. 1: S15-8. PMID 11970744 DOI: 10.3816/Cbc.2000.S.003 |
0.425 |
|
| 2000 |
Salgado R, Benoy I, Weytjens R, Vermeulen PB, Dirix LY. Serum vascular endothelial growth factor load and interleukin-6 in cancer patients - reply. British Journal of Cancer. 82: 1896. PMID 11237374 DOI: 10.1054/Bjoc.1999.1253 |
0.389 |
|
| 2000 |
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Cervek J, Fowst C, Polli A, Di Salle E, Massimini G, Piscitelli G. Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen: Results of a double-blind randomised phase III trial European Journal of Cancer. 36. PMID 11056333 DOI: 10.1016/S0959-8049(00)00240-9 |
0.441 |
|
| 2000 |
Kvinnsland S, Anker G, Dirix LY, Bonneterre J, Prove AM, Wilking N, Lobelle JP, Mariani O, di Salle E, Polli A, Massimini G. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. European Journal of Cancer (Oxford, England : 1990). 36: 976-82. PMID 10885600 DOI: 10.1016/s0959-8049(00)00041-1 |
0.337 |
|
| 2000 |
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, Di Salle E, Arkhipov A, Piscitelli G, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial Journal of Clinical Oncology. 18: 1399-1411. PMID 10735887 DOI: 10.1200/JCO.2000.18.7.1399 |
0.332 |
|
| 2000 |
Cutsem EV, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, Twelves C, Allman D, Seitz J, Schölmerich J, Burger HU, Verweij J. Capecitabine, an Oral Fluoropyrimidine Carbamate With Substantial Activity in Advanced Colorectal Cancer: Results of a Randomized Phase II Study Journal of Clinical Oncology. 18: 1337-1345. PMID 10715306 DOI: 10.1200/Jco.2000.18.6.1337 |
0.361 |
|
| 1999 |
Schrijvers D, Catimel G, Highley M, Hoppener FJP, Dirix L, Bruijn ED, Droz JP, Oosterom ATV. KW-2149-induced pulmonary toxicity is not prevented by corticosteroids: a phase I and pharmacokinetic study. Anti-Cancer Drugs. 10: 633-639. PMID 10507312 DOI: 10.1097/00001813-199908000-00002 |
0.304 |
|
| 1999 |
Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E, Morabito A, Fanelli M, Gatti C, Suzuki H, Tominaga T, Dirix LY, Gion M. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. The Cancer Journal From Scientific American. 5: 101-11. PMID 10198732 |
0.313 |
|
| 1999 |
Vermeulen PB, Van den Eynden GG, Huget P, Goovaerts G, Weyler J, Lardon F, Van Marck E, Hubens G, Dirix LY. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. British Journal of Cancer. 79: 316-22. PMID 9888475 DOI: 10.1038/Sj.Bjc.6690051 |
0.398 |
|
| 1999 |
Dirix L, Weytjens R, Salgado R, Benoy I, Vermeulen P, Prové A, Dam PV, Lemmens J. Plasma D-dimer levels, serum VEGF, b-FGF and IL-6 in metastatic breast cancer (MBC): correlation with tumour load and response to therapy European Journal of Cancer. 35. DOI: 10.1016/S0959-8049(99)80793-X |
0.373 |
|
| 1999 |
Bajetta E, Dirix LY, Fein LE, Jones SE, Cervek J, Kaufmann M, Fowst C, Polli A, Salle Ed, Massimini G. Survival advantage of exemestane (EXE, Aromasin®) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study European Journal of Cancer. 35. DOI: 10.1016/S0959-8049(99)80705-9 |
0.435 |
|
| 1998 |
Tjalma W, Van Marck E, Weyler J, Dirix L, Van Daele A, Goovaerts G, Albertyn G, van Dam P. Quantification and prognostic relevance of angiogenic parameters in invasive cervical cancer. British Journal of Cancer. 78: 170-4. PMID 9683289 DOI: 10.1038/Bjc.1998.460 |
0.342 |
|
| 1998 |
Kvinnsland S, Anker G, Dirix LY, Bonneterre J, Prove AM, Wiking N, Beider KD, Mariani O, Salle ED, Massimini G. Activity of exemestane, an irreversible, oral, aromatase inhibitor in metastatic postrnenopausal breast cancer patients (MBC) failing tamoxifen (TAM) European Journal of Cancer. 34. DOI: 10.1016/S0959-8049(98)80370-5 |
0.476 |
|
| 1997 |
Kumar-Singh S, Vermeulen PB, Weyler J, Segers K, Weyn B, Van Daele A, Dirix LY, Van Oosterom AT, Van Marck E. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. The Journal of Pathology. 182: 211-6. PMID 9274533 DOI: 10.1002/(Sici)1096-9896(199706)182:2<211::Aid-Path834>3.0.Co;2-D |
0.33 |
|
| 1997 |
Vermeulen PB, Libura M, Libura J, O'Neill PJ, van Dam P, Van Marck E, Van Oosterom AT, Dirix LY. Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma. Breast Cancer Research and Treatment. 42: 165-72. PMID 9138605 DOI: 10.1023/A:1005737524541 |
0.379 |
|
| 1997 |
Vermeulen P, Pawinsky A, Marck EV, Hubens G, Goovaerts G, Oosterom AV, Dirix LY. A prospective study on intratumoral microvessel density (IMD), p53-protein expression and prognosis in colorectal cancer European Journal of Cancer. 33: 190-190. DOI: 10.1016/S0959-8049(97)84578-9 |
0.34 |
|
| 1996 |
Dirix LY, Tonnesen F, Cassidy J, Epelbaum R, Huinink WWtB, Pavlidis N, Sorio R, Gamucci T, Wolff I, Velde AT, Lan J, Verweij J. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group European Journal of Cancer. 32: 2019-2022. PMID 8943690 DOI: 10.1016/0959-8049(96)00226-2 |
0.457 |
|
| 1996 |
Vermeulen PB, Roland L, Mertens V, Van Marck E, De Bruijn EA, Van Oosterom AT, Dirix LY. Correlation of intratumoral microvessel density and p53 protein overexpression in human colorectal adenocarcinoma. Microvascular Research. 51: 164-74. PMID 8778572 DOI: 10.1006/Mvre.1996.0018 |
0.308 |
|
| 1996 |
Dirix LY, Vermeulen PB, Fierens H, De Schepper B, Corthouts B, Van Oosterom AT. Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors--an antiangiogenic effect? Anti-Cancer Drugs. 7: 175-81. PMID 8740722 DOI: 10.1097/00001813-199602000-00005 |
0.361 |
|
| 1996 |
Dirix LY, Vermeulen PB, Van Oosterom AT, Gasparini G. Microvascular count and prognosis in colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 14: 2400-3. PMID 8708734 DOI: 10.1200/Jco.1996.14.8.2400 |
0.358 |
|
| 1996 |
Punt CJA, Humblet Y, Roca E, Dirix LY, Wainstein R, Polli A, Corradino I. Tallimustine in advanced previously untreated colorectal cancer, a phase II study. British Journal of Cancer. 73: 803-804. PMID 8611384 DOI: 10.1038/Bjc.1996.140 |
0.393 |
|
| 1996 |
Tjalma W, Pooter CD, Weyler J, Marck EV, Goovaerts G, Dirix L, Albertyn G, Dam Pv. 220The prognostic value of BCL-2 expression in patients with cervical cancer treated with radical hysterectomy and adjuvant radiotherapy Radiotherapy and Oncology. 40. DOI: 10.1016/S0167-8140(96)80229-5 |
0.377 |
|
| 1995 |
Vermeulen PB, Dirix LY, Pelgrims G, Van Oosterom AT. 5-fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Cancer. 76: 528-30. PMID 8625138 DOI: 10.1002/1097-0142(19950801)76:3<528::Aid-Cncr2820760327>3.0.Co;2-W |
0.362 |
|
| 1995 |
Creemers GJ, Wanders J, Gamucci T, Vallentin S, Dirix LY, Schöffski P, Hudson I, Verweij J. Topotecan in colorectal cancer: A phase II study of the EORTC early clinical trials group Annals of Oncology. 6: 844-846. PMID 8589027 DOI: 10.1093/Oxfordjournals.Annonc.A059328 |
0.424 |
|
| 1995 |
Wagener DJT, Verdonk HER, Dirix LY, Catimel G, Siegenthaler P, Buitenhuis M, Mathieu-Boue A, Verweij J. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study Annals of Oncology. 6: 129-132. PMID 7786820 DOI: 10.1093/Oxfordjournals.Annonc.A059107 |
0.432 |
|
| 1995 |
Dirix LY, Wouters E, Nueten Jv, Eerdeweg Wv, Oosterom ATv. Cryptorchidism and Extragonadal Germ Cell Tumor Urologia Internationalis. 55: 44-45. PMID 7571185 DOI: 10.1159/000282748 |
0.379 |
|
| 1995 |
Vermeulen PB, Roland L, Mertens V, Marek EV, Bruijn EAD, Oosterom ATV, Dirix LY. 722 Microvessel density and P53 overexpression in colorectal adenocarcinoma European Journal of Cancer. 31. DOI: 10.1016/0959-8049(95)95971-8 |
0.312 |
|
| 1994 |
Dirix LY, Meerbeeck Jv, Schrijvers D, Corthouts B, Prové A, Marck Ev, Vermeire P, Oosterom ATv. A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma Annals of Oncology. 5: 653-655. PMID 7993844 DOI: 10.1093/Oxfordjournals.Annonc.A058941 |
0.369 |
|
| 1994 |
Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders J, Franklin H, LeBail N, Verweij J. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. British Journal of Cancer. 70: 380-383. PMID 7914428 DOI: 10.1038/Bjc.1994.310 |
0.383 |
|
| 1994 |
Sternberg C, Huinink WTB, Smyth J, Bruntsch V, Dirix L, Pavlidis N, Franklin H, Wanders S, Bail NL, Kaye S. Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study. British Journal of Cancer. 70: 376-379. PMID 7914427 DOI: 10.1038/Bjc.1994.309 |
0.385 |
|
| 1993 |
Bleiberg H, Van Belle S, Paridaens R, De Wasch G, Dirix LY, Tjean M. Compassionate use of tropisetron in patients at high risk of severe emesis Annals of Oncology. 4. PMID 8364000 DOI: 10.1093/Annonc/4.Suppl_3.S43 |
0.371 |
|
| 1992 |
Bleiberg H, Van Belle S, Paridaens R, De Wasch G, Dirix LY, Tjean M. Compassionate Use of a 5-HT3-Receptor Antagonist, Tropisetron, in Patients Refractory to Standard Antiemetic Treatment Drugs. 43: 27-32. PMID 1380430 DOI: 10.2165/00003495-199200433-00007 |
0.323 |
|
| 1991 |
Dirix LY, Prove A, Becquart D, Wouters E, Vermeulen P, Oosterom Av. Tumor lysis syndrome in a patient with metastatic Merkel cell carcinoma. Cancer. 67: 2207-2210. PMID 2004341 DOI: 10.1002/1097-0142(19910415)67:8<2207::Aid-Cncr2820670834>3.0.Co;2-R |
0.33 |
|
| 1991 |
Calabresi F, Aapro M, Becquart D, Dirix L, Wils J, Ardizzoni A, Gerard B. Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. Annals of Oncology. 2: 377-378. PMID 1954183 DOI: 10.1093/Oxfordjournals.Annonc.A057960 |
0.304 |
|
| 1991 |
Coleman R, Dirix LY, Dodwell D, Tubiana-Hulin M, Body JJ, Becher R, White GK, Rubens RD, Oosterom Av, Howell A, Ford J. Phase I/II evaluation of effervescent and enteric coated oral pamidronate for bone metastases. European Journal of Cancer and Clinical Oncology. 27: 945-946. PMID 1834134 DOI: 10.1016/0277-5379(91)90158-A |
0.383 |
|
| Show low-probability matches. |